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To:  
 Kayihura Charles, your wife and all  
your three kids; you died prematurely 
My late Parents 
 
My family  
 
 
 
 
 
 
 
 
“Being deeply loved by someone gives you strength, while loving some-
one deeply gives you courage” 
Lao Tzu 
 Abstract 
Infectious diseases are a leading cause of death in sub-Saharan Africa, and 
in Rwanda diarrhea, lower respiratory and other common infections are 
linked to high mortality and morbidity. For children <5 years of age, neo-
natal/congenital disorders rank second among causes of death in Rwanda. 
However, neither the burden of, nor immunity to, fever-causing viruses in 
children and adults are currently known. 
 
Despite recent progress of vaccination in Rwanda, childhood infections 
including measles are regularly reported to WHO. To assess immunity to 
vaccine-preventable viruses, and susceptibility to emerging arboviruses, we 
investigated the seroprevalence by ELISA of IgG to MeV, RuV, ZIKV, 
CHIKV, and WNV on samples from Rwandan and Swedish blood donors 
collected during 2015 for comparative studies.  
 
The seroprevalence of MeV in Rwandan blood donors was low (71.5%) 
compared to that in Swedish donors (92.6%). This might be related to the 
previous one dose measles vaccine policy in Rwanda, (two doses were 
introduced in 2014). Yet, a comparably high seroprevalence was observed 
in older Rwandan and Swedish donors (90.4% versus 94.1%). The measles 
outbreak in Rwanda, 2010-2011, was investigated by PCR; sequencing 
revealed that these outbreak strains belonged to genotype B3, and were 
related to measles strains from neighbouring countries. 
 
Rwandan blood donors were also tested for IgG to ZIKV and RuV, both 
viruses that can cause congenital infections. The ZIKV assay showed a 
seropositivity rate of 1.4%, and all 12 samples that were positive for anti-
ZIKV IgG antibodies were negative by RT-PCR, arguing against active 
infection. Almost all women of childbearing age were found to be suscep-
tible to ZIKV. In addition, a larger proportion of Rwandan women of 
childbearing age were seronegative for RuV (10.5%) compared to males 
(6.5%).  
 
Among Rwandan donors, anti-CHIKV IgG and anti-WNV IgG antibodies 
were detected at the rates of 63% and 10.4%, respectively. The highest 
seroprevalence for both viruses was recorded within the Eastern Province, 
 with 86.7% and 33.3% for CHIKV and WNV IgG, respectively. Both Cu-
lex and Aedes mosquitoes were most prevalent in the Eastern Province. 
Swedish blood donors, as expected, showed a much lower seroprevalence 
for CHIKV, 8.5%. Surprisingly, the seroprevalence for WNV in Swedish 
donors was relatively high, 14.1%. This stimulated investigation for possi-
ble serological cross-reactivity with another flavivirus circulating in Swe-
den, i.e. TBEV. Dual seroreactivities of 78.6% and 70.3% were observed 
to WNV and TBEV in Swedish and in Rwandan donors, respectively. Fur-
thermore, 19 of the 28 Swedish sera seropositive to WNV were confirmed 
by plaque reduction neutralization test as being anti-TBEV IgG antibody-
positive, with possible cross-reactivity to WNV. 
 
This dual seroreactivity to WNV and TBEV, seen in samples from both 
countries, was further characterized on pepscan analyses of E protein linear 
epitopes. Although we could define several novel IgG epitopes of both 
viruses, we found no explanation of their serological cross-reactivity. In-
stead, this phenomenon could be related to reactivity to discontinuous 
epitopes, or to IgG directed to flaviviral proteins other than the E protein. 
Surprisingly, the strongest peptide responses detected were from a pool of 
Rwandan plasma samples that reacted to linear epitopes of the E-protein of 
TBEV rather than WNV. This finding suggests the circulation of hitherto 
undiscovered tick-borne flaviviruses in Rwanda, which may share con-
served epitopes with TBEV. 
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SAMMANFATTNING PÅ SVENSKA 
Sammanfattning på svenska 
Trots förbättrad profylax och behandling under senare år orsakar infekt-
ionssjukdomar fortfarande en betydande dödlighet i centralafrikanska län-
der inklusive Rwanda. Ett allmänt barnvaccinationsprogram med hög 
täckningsgrad har införts i landet, men grundläggande data gällande be-
folkningens immunitet mot viktiga infektionssjukdomar som mässling och 
röda hund saknas helt. Vidare har förekomst och spridning av myggburna 
virus som Zikavirus (ZIKV), Chikun-gunyavirus (CHKV) samt West Nile-
virus (WNV) ej undersökts i Rwanda. 
 
Målsättningen med avhandlingsarbetet har varit att kartlägga immunitet i 
form av IgG-reaktivitet (s.k. seroprevalens) mot dessa fem virus hos blod-
givare från olika regioner inom Rwanda. Vad gäller mässling och röda 
hund kan arbetet ge underlag för riskbedömningar avseende utbrott av 
dessa två virus, och för mässling kan även effektiviteten av vaccinpro-
grammet, som startades 1982, bedömas. För mässling och röda hund har 
även diagnostiska data insamlats rörande akuta sjukdomsfall, samt för fos-
terskador efter infektion med röda hund under graviditet. Seroprevalensun-
dersökningar på samma material av blodgivare har även genomförts mot 
tre kliniskt viktiga myggburna virus som samtliga ursprungligen upptäck-
tes inom Rwandas geografiska närområde: ZIKV, CHIKV och WNV. 
 
I arbete I fann vi en betydligt lägre immunitet mot mässling, mätt som 
seroprevalens, hos blodgivare från Rwanda (71.5%) jämfört med svenska 
blodgivarkontroller (92.6%). Även antikroppsmängden, mätt som OD-
värden hos de seropositiva individerna, var lägre hos Rwandiska blodgi-
vare jämfört med de från Sverige. Trots den lägre graden av immunitet 
minskade utbrotten av mässling kraftigt under studieperioden, och nya fall 
inträffade framförallt i områden som gränsade till Burundi och Kongo-
Kinshasa. Ett tydligt undantag från denna positiva trend var perioden under 
och efter folkmordet 1994, då vaccineringen nästan upphörde vilket ledde 
till omfattande mässlingsutbrott. 
 
I arbete II fann vi en god immunitet mot röda hund, trots att allmän vacci-
nation infördes först 2013. Det bör dock påpekas att >10% av kvinnliga 
blodgivare i fertil ålder i Rwanda befanns vara mottagliga för röda hund, 
 vilket understryker vikten av fortsatt vaccination. I samma arbete fann vi 
att i princip hela befolkningen var seronegativ för ZIKV, ett myggburet 
virus med fosterskadande potential. Fyndet betyder att gravida kvinnor 
skulle kunna drabbas av ZIKV-infektioner under graviditet, med risk för 
fosterskadande effekt, om detta virus skulle börja spridas i landet. Arbetet 
är en av få studier som undersökt immunitet mot ZIKV i Afrika, och resul-
taten stöder vikten av att en diagnostisk beredskap för detta virus införs i 
Rwanda. 
 
Våra studier av immunitet mot myggburna virus fortsatte i arbete III, där 
förekomst av IgG mot CHIKV och WNV analyserades i samma blodgi-
varmaterial. Eftersom kommersiella tester av serologi mot CHIKV saknas, 
utvecklade vi en egen metod baserad på ett virusprotein som utvecklats 
som en vaccinkandidat. Antigenet fungerade väl med positiva och negativa 
kontrollsera, och vi kunde bestämma seroprevalensen för CHIKV till 63% 
hos rwandiska och 8.5% hos svenska donatorer. Seroprevalensen var allra 
högst i den östra provinsen, som också uppvisade störst förekomst av 
myggvektorn Aedes. Vid analys av IgG mot WNV fann vi, något förvå-
nande, att seroprevalensen för detta virus var högre i Sverige (14%) än i 
Rwanda (10%). Eftersom fästingburet encefalitvirus, TBEV, ett relativt 
närbesläktat flavivirus, förekommer i Sverige men inte i Rwanda, analyse-
rade vi IgG och även neutralisationsförmåga mot detta virus. Vi fann teck-
en på sannolik serologisk korsreaktivitet, som vi utredde närmare i Arbete 
IV. 
 
Vi använde därvid en detaljerad metod (pepscan) för att kartlägga linjära 
IgG-epitoper hos glykoprotein E från WNV och TBEV. Vi kunde inte på-
visa någon korsreagerande linjär epitop, trots likheter i aminosyresekvens 
mellan de två proteinerna. Istället fann vi flera specifika epitoper för bägge 
virus när vi undersökte poolade prover från Rwanda och Sverige. Ett in-
tressant fynd var att den starkaste peptid-reaktiviteten påvisades hos rwan-
desiska prover gentemot TBEV. Fyndet kan tala för att hittills oupptäckta 
fästingburna flavivirus förekommer i Rwanda. 
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1 Introduction 
1.1 Background 
1.1.1 Infectious diseases in Africa  
 
Infectious diseases are considered as a main health problem in Africa despite 
the important progress made in prevention, diagnostics and treatment during 
recent years. In sub-Saharan Africa, infectious diseases continue to be reported 
as the leading cause of death, and this mortality is dominated by gastroenteric 
and respiratory tract infections (Figure 1.1). Viruses cause most of these infec-
tions. In addition, vector-borne zoonotic infections caused by flaviviruses and 
bunyaviruses often show high prevalence in Africa. 
 
 
Figure 1.1. Top 10 causes of deaths in low-income countries in 2016. Source: World Health 
Organization (WHO) 2018. 
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As an illustration of the clinical importance of viral infections in Africa, the 
World Health Organization (WHO) reported 36.9 million cases of human immu-
nodeficiency virus in 2017, where newly infected accounted for 1.8 million 
(5%). The same year, 940,000 deaths related to HIV were recorded worldwide. 
Further analysis of this mortality revealed that the WHO Africa Region was the 
most affected with around 70% of deaths, and this continent alone accounted for 
over two thirds of the total new HIV infections globally [1, 2]. 
 
Another example is the recent large outbreak of ebola in West Africa, which 
affected 28,000 where over 11,000 cases died. This demonstrated the lack of 
preparedness in Africa to respond to rapidly emerging health threats, as well as 
the fragility of existing health facilities [3].   
 
Since the late 1800s, developed countries have alleviated the burden of infec-
tious diseases by improving living conditions such as housing and access to 
clean water. Both these conditions are still poor in Africa. However, the intro-
duction of vaccines during the 20th century, on a global scale, has lead to en-
hanced control of infections. This measure has rapidly been extended to low and 
middle-income countries, including Africa, with beneficial results [2]. 
1.1.2 Vaccination  
Immunization, also known as vaccination, is one of the two most effective 
means to prevent infectious diseases, the other being improvements in sanitation 
and general living conditions. The discovery of immunity as a way to abrogate 
the occurrence of infectious diseases is a cornerstone of preventive medicine. 
Most important, infections are effectively hindered by active immunization 
where pathogens are introduced in form of vaccines. These can be made either 
from live attenuated infectious agents, or as inactivated, or detoxified agents or 
their subcomponents, which are administered to humans or animals in order to 
produce specific antibodies. Another, less efficient, way could be a passive im-
munization, for example injection of immunoglobulins, where exogenous anti-
bodies are provided to ensure temporary protection against a targeted infection, 
as is the case with transplacental transfer of antibodies from the mother to the 
fetus [4]. 
 
Immunization started many centuries ago with variolation, the technique of 
inoculation of fluid from smallpox lesions into the skin of non-immune subjects. 
However, this practice showed severe side effects. Indeed, immunization did not 
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become a successful and more acceptable procedure until 1796 when Jenner 
inoculated fluid from cowpox (vaccinia) vesicular lesions into the skin of an 
exposed subject who mounted protection against smallpox [4]. This discovery 
was based on the observation by Jenner that milkers, who were exposed to cow-
pox in their work, were naturally immune to smallpox. 
 
During the early 20th century, a rapid development of vaccines followed. As 
one example, Max Theiler discovered in 1930 that yellow fever virus can be 
attenuated by serial passage in mouse brain and chicken embryos, resulting in a 
successive reduction of its pathogenicity in monkeys. He also developed a test 
for measuring protective antibodies in mice [5]. Theiler’s discoveries were es-
sential for the production of the live virus vaccine against yellow fever that is 
still in use today, and he was awarded the Nobel Prize in medicine in 1951 for 
his work. Further progress was made by the implementation of cell cultures for 
vaccine development against a number of viruses such as polioviruses. Such 
vaccines could either be live attenuated or inactivated by formalin treatment. 
 
The developed vaccines were then utilized in vaccination programs that grad-
ually became implemented globally. Great results were achieved with the 
worldwide eradication of devastating diseases such as smallpox in humans in 
1980, and of the measles-like rinderpest in cattle in 2011 [6]. The eradication 
through vaccination against other diseases such as polio, measles, rubella, and 
mumps is in progress [6-8].  Through a combination of vaccination programs 
and/or improved living conditions, the global incidence and burden of disease of 
many other infections have dramatically decreased during the last decades.  
 
 
1.1.2.1 Vaccination in Africa 
 
The preventive approach of controlling infectious diseases by vaccination 
was extended to Africa during the second half of the twentieth century [2]. From 
that period on, immunization coverage has gradually increased over the years. 
Diphtheria-Tetanus-Pertussis vaccination coverage increased considerably in 
Africa, from 57% in 2000 to 76% in 2015. As a result, vaccine-preventable dis-
eases also decreased substantially, where for example deaths associated with 
measles were reduced by 86% between 2000 and 2014 [9].  
 
Despite that progress, important disparities within and between countries due 
to social conflicts, health care system not functioning well, poverty or poor allo-
cation of resources and inconvenient infrastructure is apparent (Figure 1.2). In 
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2016, Nigeria, Ethiopia, Democratic Republic of the Congo (DRC), Southern 
Soudan and Guinea were reported as the African countries with most under-
immunized children [10, 11]. 
 
Figure 1.2. World: Immunization coverage with 1st dose of measles containing vaccines in 
infants, 2017. Most variations in vaccination coverage are recorded from the Af-
rican continent where all the 8 countries, with vaccination coverage below 50%, 
are located. Source: WHO 2018. 
 
1.1.2.2 Vaccination program in Rwanda 
 
The vaccination program has been operational in Rwanda since 1980 and cur-
rently, immunization services are integrated into the routine activities of each 
health center. The program was implemented progressively (Table 1.1) with the 
introduction of the vaccines against tuberculosis (BCG), poliomyelitis (OPV), 
and tetanus for pregnant women, in 1980; diphtheria, neonatal tetanus, and per-
tussis (DTP) in 1981, later combined with hepatitis B and haemophilus influenza 
type B (DTP-HepB-Hib) in 2002; measles in 1981, also combined with rubella 
(MR) in 2013; streptococcus pneumoniae (PCV) in 2009; rotavirus in 2012; and 
human papilloma virus (HPV) in 2011 [12, 13].  
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Table 1.1 Rwandan immunization schedule 
Table 1.1 Immunization program in Rwanda including type of vaccines and their admin-
istration schedule, with the year of implementation [12]. 
In addition to those vaccines provided to the general population, yellow fever 
vaccine can be administered to anyone who seeks it, mainly to persons travelling 
to areas where risk of exposure to yellow fever infection is high. This is the only 
vaccine paid for by the recipient in Rwanda. Note that proof of yellow fever vac-
cination is mandatory for travellers coming into Rwanda from countries where 
there is risk of contracting this infection. 
 
All vaccines are managed and only provided by the Extended Program of 
Immunization under the Rwanda Biomedical Center [14] and the Ministry of 
Health. There are no other in-country institutions or private companies providing 
vaccines. 
 
The main outcomes of monitoring the immunization program efficacy are 
based on the vaccination coverage rate and incidence of cases reported. These 
criteria are used globally and are the only widely utilised in Africa. In addition, 
seroprevalence studies, which tests the level of IgG antibodies developed against 
viruses targeted by vaccines, can be a useful complement. In Rwanda, the re-
ported vaccination coverage for the measles vaccine is > 95% [13]. 
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1.1.3 Serosurveillance of infectious diseases  
Seroepidemiology, the study of the prevalence of antibodies in serum or in 
other biological materials, serves as an important parameter to monitor the im-
pact of infectious diseases in defined populations. To this end, direct assay of 
IgG antibodies as a measurement of the developed immunity is of paramount 
interest. Thus, seroepidemiology is an efficient means for the evaluation of the 
necessity of immunization to a given pathogen, and of the need of implementa-
tion of vaccination or other infection control programs [15]. 
 
In developed countries, serological surveillance has long been of importance 
for the formulation of national health policies, including the design of the vac-
cination programs. In England and Wales, serum samples were collected from 
1986 to 1996, before the introduction of the MMR vaccine in 1988, and serolog-
ical surveillance provided baseline data on immunity to these infections that di-
rectly influenced their national vaccination policy. To exemplify this, the 1994 
measles and rubella campaign with the introduction of a second dose of MMR at 
4 years of age was based on seroimmunity data. On the other hand, the decision 
not to implement a universal hepatitis B vaccination programme in this region 
was also founded on seroepidemiology reports [16, 17].  
 
In addition to national serological surveillance programs within European 
countries, a European seroepidemiology network (ESEN) project, financed by 
the European Union, was established in 1996. This network co-ordinated and 
harmonised the serological surveillance of immunity to a number of vaccine-
preventable infections and evaluated existing vaccination programs. Based on 
the recorded successes, they extended the project from 2001 to 2005 to investi-
gate the seroepidemiology of several other infections and included new partner 
countries in southern and Eastern Europe [18, 19].  
 
 
1.1.3.1 Antibody response and immunity to viral infections 
  
The aims of viruses to survive and multiply require them to interact with the 
host cells and exploit their metabolism to their own benefit. Immune cells coun-
teract the viral invasion and dissemination by innate or non-antigen specific and 
adaptive or antigen specific immune responses.  
 
The innate immune response is stimulated by identification of viral constitu-
ents specific to different classes of pattern-recognition receptors (PRRs) such as 
the Toll-like receptors (TLR), retinoic acid inducible gene-I (RIG-I)-like recep-
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tor (RLR), nucleotide oligomerization and binding domain (NOD)-like receptor 
(NLR). These receptors are important in initiating signaling for production of 
type I interferons (IFNs), proinflammatory cytokines and interleukin-1ß which 
play a role in clearing the infection, inducing apoptosis of infected cells and 
providing immunity to uninfected cells.  Cytokines also stimulate recruitment of 
immune cells to the site of infection, thereby containing the infection followed 
by its clearance, but also aiding presentation of viral antigens for activation of 
the adaptive immune response [20, 21].  
 
The adaptive immunity functions through T and B lymphocytes, which act in 
complementarity. Following the first exposure to the wild type virus or to a vac-
cine containing viral particles, the host responds directly through T lymphocytes 
where within 7-10 days of exposure, 50-60% of CD8 T cells are virus specific. 
Later, this response decreases progressively to remain with 1-10% of memory 
splenic CD8 viral specific cells. Thereafter, B lymphocytes response in form of 
IgG antibodies increases from 2 to 4 weeks of the infection and may last life-
long. 
 
Following a secondary exposure to the same viral antigens, both T and B 
lymphocytes display antigen-specific memory where antibodies rise quickly in 
quantity and the peaks last longer than after primary challenge. Cytotoxic T cells 
also respond very quickly.  
 
Neutralization of viruses by antibodies occurs mainly by IgG attachment to 
the viral site (the epitope) that could potentially interact with the cell-surface 
receptor of the host, and through lysis of the infected cell by complement. Other 
antibodies aggregate the infectious particles, thus reducing infectiosity of new 
cells. 
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The two main classes of antibodies used for serodiagnosis, IgM and IgG, be-
have differently with regards to the kinetics of the viral infection (Figure 1.3). 
The IgM appears early and mounts the initial antibody-mediated immune re-
sponse by intercepting the virus and reducing virus binding to specific host re-
ceptors, and by aggregating the viral particles, thereby decreasing their 
infectivity. Later, and on secondary exposure, most IgM-producing cells switch 
to IgG, which is the major complement-binding and opsonizing antibody [22].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3  IgM and IgG antibodies response to primary and secondary exposure to a viral 
   antigen. 
1.1.4 Zoonotic diseases  
Zoonotic diseases are naturally occurring animal infections that can be trans-
mitted to humans. They differ in their etiologies, which can be viral (ebola fever, 
SARS, avian flu), bacterial (brucellosis, anthrax, tuberculosis), fungal (crypto-
coccosis, histoplasmosis) or parasitic (taeniasis, cryptosporidiosis). In addition, 
they manifest themselves with variable virulence; some occur with minor clini-
cal signs such as sindbis virus while others, for example ebola virus, present 
severe complications with massive hemorrhage and dehydration leading to high 
mortality [23]. 
 
Persistence of zoonotic diseases in nature requires an appropriate animal res-
ervoir (swine, sheep, camel, non-human primate, fox, rodents, bats, bovine, 
birds, etc) from where the pathogen might infect humans by direct contact with 
contaminated materials from the animal, or by an intermediate vector such as 
mosquitoes, ticks, flea, and flies [24, 25].  
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The ability of genetic adaptation through mutation influences the capacity of 
a given pathogen to fit within several different species, enabling the maintenance 
of the zoonotic life cycle including animals-vectors-humans. Several important 
zoonoses are of viral etiology and most commonly, such agents belong to the 
RNA group of viruses due to their frequent genetic variation resulting from a 
high RNA polymerase error rate and the lack of proofreading ability during their 
replication cycle [26-28]. Despite this fact, zoonotic RNA viruses can be re-
markably stable under certain circumstances. 
 
Though most zoonotic infections maintain the non-human to human life cy-
cle, surprisingly, some evolve to become fully adapted to a transmission cycle 
exclusively within humans (eg: ebola, CCHFV, influenza A subtype H5N1, 
coronavirus, HIV, measles, etc) [29]. 
 
The global epidemiology of infectious diseases shows ongoing changes with 
arboviruses expanding to reach geographical areas where they were nonexistent 
before. This can often be influenced by alteration of the environment, such as by 
climate change favouring competent vectors. In addition, global trends in trade, 
travel and urbanization are factors resulting in enhancement of outbreaks of 
emerging zoonotic infections.  
 
 
1.1.4.1 Mosquito-borne viruses in Africa 
 
The high biodiversity found in Africa is also valid for important species of 
mosquitoes, which in turn have the potential to propagate many different viral 
pathogens. Such a rich bioenvironment might have constituted a strong network 
enabling the evolution of zoonotic infections. Over millions of years, most like-
ly, viruses have adapted their life cycles to specific mosquito vectors and animal 
reservoirs. Later, these transmissions have also included humans because of their 
long coexistence with animals and vectors [30]. Among the most medically im-
portant mosquito-borne viruses reported from Africa, some are endemic and 
associated with outbreaks in humans such as yellow fever (YFV), dengue, or, in 
animals, Rift Valley fever. Many other viral infections such as Banzi, Bwamba, 
Bunyawera, Germiston, Ilesha, Lumbo, Middelburg, Ndumu, Ngari, Ntaya, 
O’nyong-nyong, Pongola, Semliki Forest, Shuni, Simbu, Sindbis, Spondweni 
and Wesselsbron were reported, often with nonsignificant clinical symptoms. 
However, benign viruses might suddenly surprise the global community, espe-
cially if introduced within an environment with immunologically naïve popula-
tions as recently occured with Zika virus in Brazil [31, 32], West Nile virus in 
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America [33] and chikungunya virus (CHIKV) in the Caribbean Islands [34, 35]. 
Interestingly, no serious outbreaks of these viruses have been reported recently 
from Africa although they all originate from this continent [36]. 
1.1.5 Geographical background of Rwanda  
Rwanda is located in Central-East Africa, south of the equator between lati-
tude 1°4’ and 2°51’S, and longitude 28°63’ and 30°54’ E. It is a landlocked 
country with an area of 26,338 square kilometers, bordered by Uganda to the 
north, Burundi to the south, Tanzania to the east and the Democratic Republic of 
the Congo to the west. 
The country is situated at high altitude with the lowest point at 950 meters 
and the highest at 4,507 meters above the sea level. Mountains are predominant 
within north, central and western regions while the eastern region is rich in sa-
vanna, swamps and plains.  
The climate in Rwanda is sub-equatorial with an average yearly temperature 
of 18.5°C. This climate is also known to change from year to year, with extreme 
changes in rainfall that sometimes result in flooding or in drought [37]. Due to 
those unusual rainfalls with flooding, there is a rise in reproduction of mosqui-
toes that can vector diseases. The recent outbreak of RVF, reported since May 
18, 2018 within four districts of the Eastern Province, was believed to be linked 
to the heavy rains and floods that hit Rwanda during March and May, 2018 [38].  
1.1.6 Mosquito-borne diseases in Rwanda 
Despite having an ecological environment (most of the country being under 
2,300 m above sea altitude) suitable for mosquitoes [39], and being a sub-
Saharan African country where most arboviruses originate, little is known about 
mosquito-borne diseases in Rwanda. One exception is malaria, which is a para-
sitic disease that has been controlled through a national program within RBC and 
the Ministry of Health. In this context, the current outbreak of RVF might be a 
warning sign of other possible mosquito-borne viral infections which have not 
been controlled for, especially those sharing the same vector as RVF [38]. We 
contributed within this field by assessing the seroprevalence, from blood donors, 
to CHIKV, West Nile virus and Zika virus that are transmitted by the two mos-
quito species Culex and Aedes that also vector RVF. 
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In addition, we explored serologically, for the first time in Rwanda, protec-
tive response from immunization to measles and to rubella viruses among blood 
donors.  
 
1.2 Measles virus 
1.2.1 Historic aspects of measles  
The first measles-like clinical characteristics were reported as early as the 9th 
century when a Persian physician Abu Becr (known as Rhazes) differentiated 
measles from smallpox. However, measles might have been described already in 
the 6th century as a modification of smallpox, under the name of hasbah (erup-
tion) in arabic [40].  
Epidemics of rash-like diseases have been reported from Europe and the Far 
East since ancient times. It is hypothesized that measles may originate from the 
Middle East, which in those times had sufficient population density for the main-
tainance of transmission cycles of measles. It took until the 11th and 12th centu-
ries before those epidemics of what could have been measles infections were 
identified as a childhood disease, in 1224 [41]. 
In differentiating those lesions from plague, the Europeans gave them the 
name of “morbilli” from the Italian meaning “little disease”. Later, in 1763, the 
disease was named as measles after Sanvages who called it rubeola from the 
Spanish [40]. 
 
High morbidity and mortality associated with measles was observed among 
non-immunized populations. From the measles epidemic that occurred in the 
Faroe Island in 1846, the Danish physician Peter Panum described this disease as 
an airborne, highly contagious infection, with an incubation period of 14 days, 
but conferring lifelong immunity. A mortality rate of 26% associated with mea-
sles was reported on the Fiji Island in 1875. The introduction of Old World dis-
eases, especially of measles and smallpox, through European exploration of the 
New World, into naïve native Amerindian communities was associated with at 
least 56 million deaths [40, 42]. 
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1.2.2 Virology: genes, proteins and replication 
Measles virus (MeV) is a spherical, enveloped virus containing nonsegment-
ed, single-stranded, negative-sense RNA. This large (100-300 nm) pleomorphic 
virus belongs to the Morbillivirus genus of the Paramyxoviridea family. 
It is closely related to the bovine rinderpest virus (RPV), and MeV might 
very well originally have emerged from that virus. The bovine-to-human transfer 
might have occurred as a consequence of livestock farming, with cattle and hu-
mans living in a close environment [43]. 
 
The analysis of genes encoding the envelope proteins N and H showed that 
the Time to the Most Recent Common Ancestor (TMRCA) of the currently cir-
culating MeV strains was 1921 and 1916, respectively, for these two genes. Of 
interest in this context, the date of divergence between MeV and RPV was esti-
mated to have taken place already during the 12th century [41]. It can be noted 
here that in 2012, after a long and tedious campaign including veterinarians, 
RPV was the 2nd virus ever to be eradicated from our planet [44]. 
 
The MeV genomic RNA has a molecular weight of 4.5 kDa, containing 
16,000 nucleotides (nt) and six genes encoding six major structural proteins: the 
membrane envelope (hemagglutinin H and fusion F proteins), the matrix M pro-
tein, and the three proteins belonging to the nucleocapsid complex, nucleopro-
tein N, phosphoprotein P and large protein L (Figure 2.1).  
 
 
Figure 2.1 Schematic representation of (a) MeV proteins and their location on the virus 
particle and (b) the linear MeV genome [45].  
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Entry of MeV particles into the host cells is initiated by the H protein, which 
facilitates attachment to the cell surface, via CD150/SLAM and nectin-4/PVRL4 
host receptors for wild-type virus, or CD46 receptors for the vaccine strains, 
followed by fusion mediated by the F protein. Post entry, the matrix M protein 
facilitates interaction between envelope proteins and the nucleocapsid for matu-
ration of virions.  The nucleocapsid N protein surrounds the genetic material, the 
viral RNA. In addition, the P and L proteins bind to the RNA and serve in tran-
scription and replication. The two additional nonstructural proteins C and V 
(both encoded from the P gene) most probably also play a role in the regulation 
of transcription and replication of the virus [46-48]. 
 
The viral replication pattern often determines the degree of acquired muta-
tions. Viral mutant strains, also called genotypes, occur according to the amount 
of viral replication. The more the type of virus replicates, the more diverse it 
becomes; therefore, the transformation into new genotypes by genetic drift in-
creases with multiplicity. Escape mutants within immunodominant viral genes 
may induce new viral serotypes, which can be resistant to vaccines or be respon-
sible for spread within hitherto immune populations. To this end, it is vital to 
ensure a close and frequent monitoring of genotype emergence, especially from 
pathogens targeted by vaccines. Such preparedness includes implementation of 
preventive measures against unexpected massive outbreaks, as was exemplified 
by recent outbreaks of ZIKV and Ebola virus.  
In addition to antigenic drift, viruses may evolve through antigenic shift, as is 
the case for influenza virus type A. This virus has a yearly mutation rate of 1x 
10-3 to 8x10-3 amino acid substitutions per site in addition to the 256 (28) possi-
ble combinations of the eight gene segments from reassortment between differ-
ent types of influenza virus, with the potential for switching to a new serotype 
almost yearly [49, 50]. This is the reason why the influenza vaccine is often re-
newed yearly to respond to the circulating serotype of a certain season. Due to 
the practice of yearly influenza vaccination, it has been observed that the IgG 
antibody quantities against influenza virus antigens are much higher, 50x, 10x 
and 5x respectively, as compared to those directed against mumps, measles, and 
rubella viruses. The presence of high levels of anti-influenza virus IgG might 
interfere with the clearance of antigens from the newly administered vaccine, 
therefore reducing or inhibiting its protective effect [51]. Determination of the 
optimal timing for vaccination of infants to avoid interference with maternal 
antibodies could influence the vaccination pattern of highly mutant viruses. 
Some vaccines fail to protect seronegative individuals or, even worse, other vac-
cines may increase the severity of the infection as observed with dengue virus 
vaccines [52-54]. With regards to these pitfalls in vaccination, but also to the 
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dynamics of viral genetics, regular surveillance of MeV genotypes, which pre-
sent with ever expanding clades (Figure 2.2), is essential. Surveillance studies 
must also focus on the differences reported in neutralization testing of the vari-
ous genotypes [55].  
 
 
Figure 2.2 Phylogenetic tree of MeV, with branches colored according to the geographic 
origin of the different strains [56].  
Genotyping studies of MeV are often based on nucleotide sequence analyses 
of the H and/or N genes. Nucleotide variability within those genes is low and is 
estimated at 8% from sequences of all strains analysed. The most variable site 
was found to be the 450-nucleotide region, with 12% variability between wild 
type MeV, which encodes the COOH-terminus of the N protein. Records of the 
global distribution of MeV, updated in 2015 by WHO, revealed eight clades of 
MeV, namely A, B, C, D, E, F, G and H. Subsequently, twenty-four genotypes, 
designated A, B1, B2, B3, C1, C2, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, 
D11, E, F, G1, G2, G3, H1, H2 were identified. However, 18 of these genotypes 
were last detected until 2011 and only six genotypes are reported thereafter. The 
currently circulating MeV genotype H1 was found in Western Pacific, Eastern 
Mediterranean Europe, Southeast Asia and America regions. The B3 genotype 
was endemic in sub-Saharan Africa before 2014, but has since been found to be 
distributed worldwide where it was associated with outbreaks within 49 coun-
tries, the largest one being in the Philippines. The genotype D8 was reported 
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globally in 2014 but previously it was only found in southeastern Asia, particu-
lary in India. Genotype D4 was reported from Southeastern Asia, Western Pacif-
ic, Eastern Mediterranean region, Europe, America and Southern Africa. The D9 
genotype was identified in Europe, Southeastern Asia and Western Pacific re-
gions while G3 was reported in Southeastern Asia and Western Pacific regions 
[57-62]. Some of those genotypes were linked to endemic transmission and oth-
ers to imported cases. 
 
Despite the existence of all those various genotypes, MeV presents with only 
one serotype due to the similarity of surface antigens across all MeV strains. 
This permits the potential neutralization of all measles genotype strains by serum 
samples from vaccinees or subjects infected with measles, although neutralizing 
titers can vary for the different genotypes [63]. One conserved region is the core 
part of the nucleocapsid protein (Ncore), which is immunodominant as regards 
antibody response [64]. However the protective role of these antibodies is not 
fully known.   
 
As mentioned above, the replication of MeV starts by the attachment of the H 
protein to host cell surface receptors (CD150/SLAM, CD46 and nectin-
4/PVRL4), which activate conformational changes in the F protein, facilitating 
fusion of the viral envelope with the plasma membrane, and the release of the 
ribonucleoprotein complex into the cytoplasm. The viral RNA then serves as 
template for the RNA-dependant RNA polymerase (encoded by L gene) and is 
transcribed directly into viral mRNA; there is no DNA intermediate. H and F 
proteins facilitate the fusion of infected cells with neighbouring cells resulting in 
the formation of multinucleated giant cells (syncytia), which are a hallmark of 
MeV infection [48, 65, 66]. 
1.2.3 Transmission, epidemiology and clinical presentation  
MeV only infects humans and non-human primates. It is highly contagious 
and the infection takes place through inhalation of viral particles produced main-
ly by coughing or sneezing. In naïve populations, a single measles case might 
infect more than 90% of his/her close contacts to cause severe large outbreaks 
with high morbidity and mortality. The peak of MeV replication takes place 
within the respiratory tract, and the most contagious period, occurs 4 days before 
the onset of clinical signs and continues until 4 days after the appearance of rash. 
This makes it difficult to isolate the index case and stop the spread of the infec-
tion within the community. Transmission of MeV within physicians’ offices, 
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waiting areas in hospitals, sport complexes, and congregation at water collection 
sites have been reported [67, 68]. However, MeV confers a lifelong immunity 
and consequently remains a childhood disease within highly endemic areas.  
 
There is no reservoir host apart from humans. Thus, to maintain persistence 
of MeV and continuous transmission, a large human population ranging between 
250,000 and 500,000 at least is required [41, 69-71]. This is the reason why 
small and bottleneck populations often are non-immune to measles. As one ex-
ample, the native populations of the Americas were highly susceptible to mea-
sles during the Spanish invasion from the 16th century an onwards. 
 
Before the introduction of the live attenuated MeV vaccine in 1963, measles 
was associated with a high mortality among children. In the pre-vaccination era, 
there were around 135 million cases with 7-8 million of deaths yearly, world-
wide. Following improvement of socioeconomic conditions with rich nutrition 
and access to well-equipped health facilities, cases of measles-related death de-
creased. The introduction of the measles vaccine in 1963 was associated with the 
control of the disease. Unfortunately, a rise of measles-related mortality and 
morbidity is presently recorded, especially among children, as a consequence of 
low immunization coverage due to a vociferous anti-vaccination movement in 
Europe. In addition, war, poor socioeconomic status, lack of appropriate health 
infrastructure, and poor management of natural disasters in developing countries, 
have also exacerbated the problem of low immunization coverage [72-74]. 
 
Recently, over 41,000 measles cases were identified in the European region 
from January to June 2018. This number, recorded during only a half year, far 
exceeds total cases reported yearly for the last 8 years in Europe. The highest 
and lowest number of cases reported from 2010 to 2017 were 23,927 and 5,273 
for the years 2017 and 2016, respectively [75]. Globally, the number of clinically 
confirmed cases of measles reported between January and August 2018, exceed 
the total number recorded for 2017 (83,951 vs 75,552) confirming the decline of 
control measures within the WHO region [76].  
 
Clinical characteristics of measles infection appear around 10 to 14 days after 
infection. Symptoms start with mild to moderate fever, persistent cough, runny 
nose, conjunctivitis and sore throat followed by high fever. The rash, which ap-
pears first on the face, spreads down to the body, and lastly to the extremities, 
including palms and soles. Koplick spots, a rash present on mucous membranes 
of the mouth, are considered pathognomonic for measles (Figure 2.3). It occurs 
from 1-2 days before the rash, to 1-2 days after the rash. 
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Figure 2.3 Clinical manifestations of measles. The maculopapular skin rash (c), severe des-
quamation of maculopapular skin rash (d) and the Koplik spot (e; white arrows). 
Reproduced with permission from Springer Nature [66]. 
Recovery from the disease might be spontaneous with measles rash receding 
gradually, but the infection might also be associated with severe complications, 
which could result in death. Among such complications are otitis media, bron-
chitis, laryngitis (croup), and pneumonia, which often is fatal among immuno-
compromised patients. In addition, MeV is a neurotropic virus and encephalitis 
may occur directly after the infection or later, after many months or even years 
after the acute stage. Among pregnant women, measles infection may cause pre-
term labor, low birth weight or maternal death.  Another rare complication, the 
subacute sclerosing panencephalitis (SSPE), a degenerative central nervous sys-
tem disease, is reported to be due to the persistence of measles virus infection 
within the brain. Onset occurs on an average 7 years after measles (range 1 
month-27 years) [68, 77, 78] 
 
   
1.2.4 Diagnosis  
The clinical diagnosis of measles is often confirmed by the detection of IgM 
response, which may persist up to 1-2 months after the onset of rash. Up to 20% 
of IgM results may be falsely negative if samples are collected within the first 72 
hours of appearance of rash. IgG antibodies to measles appear later, and measles 
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infection can be confirmed by comparing two samples collected at different time 
points, where the first sample is collected directly after the onset of the rash and 
the second taken 10-30 days later. Both samples should be analysed together ie. 
in parallel, by same test. Acute measles is confirmed if the second sample shows 
a four-fold rise in MeV antibodies titer as compared with the first sample. 
 
Modern techniques of molecular biology also contribute to the diagnosis by 
demonstrating measles RNA, for example by RT-PCR, in body fluids such as 
blood, urine, nasopharyngeal aspirates, or throat swabs. Isolation of MeV can be 
performed from the same sample materials. This method is not recommended for 
routine diagnosis. However, isolation followed by genetic sequencing plays an 
important role in the molecular epidemiologic surveillance of the measles strains 
circulating in the community, and in determining the possible origin of the mea-
sles outbreak [43].    
1.2.5 Treatment and prevention  
There are no antiviral drugs available against MeV. Infected patients are 
treated with supportive therapy, which may include antipyretics and fluids. Ap-
propriate antibiotics are considered for bacterial superinfections. Vitamin A is 
also used to decrease the severity of measles, especially among patients with 
vitamin A deficency or the malnourished. However, this vitamin was reported to 
reduce seroconversion in vaccinees, and therefore is not recommended for ad-
ministration during or directly after vaccination [68].  
 
The overall most effective prevention against measles is the administration of 
the live attenuated vaccine that confers a persistent immunity to measles. Fever 
and rash may be manifested in about 5-15% of children 7 days after vaccination. 
Passive immunization, with immunoglobulin, against measles is sometimes rec-
ommended. This should be given within 6 days of an exposure to abrogate infec-
tion, especially to children on chemotherapy, on radiotherapy or patients 
immunosuppressed by HIV [68].   
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1.3 Rubella virus 
1.3.1 Virology: genes, proteins and replication  
Rubella virus (RuV) is a single-stranded, nonsegmented, positive-sense RNA 
virus and the only member of the genus Rubivirus belonging to the Togaviridae 
family. RuV is also the only known togavirus not transmitted by a vector.  
 
De Bergen, a German physician, first described infection from RuV in the 
early 1800s. He called it Rõtheln, later known as German measles because it 
caused a milder form of exanthema compared to measles. In 1866, H. Veale pro-
posed the name Rubella [79].   
 
Rubella viral particles (virions) have variable morphology, where most are 
spherical and measure between 57-86 nm of diameter [80]. The viral genome 
contains two open reading frames (ORFs) where the short one of 3,189 nucleo-
tides encodes three structural polypeptides: two glycoproteins, the E1 and E2, 
which spike from the lipid membrane envelope; and the capsid protein C con-
taining proline and arginine residues, which bind to the viral RNA to form the 
nucleocapsid.  The long RuV ORF of 6,345 nucleotides encodes two nonstruc-
tural polypeptides, the p150 and p90, which are important during viral replica-
tion.  
 
RuV has only one serotype. The glycoprotein E1 was found to be the most 
dominant antigen and initiates the binding of the virus to the host cell receptor. It 
also facilitates membrane fusion in presence of low pH and calcium ions. E2 
glycoprotein binds the capsid protein to the membrane and is responsible for the 
folding and transportation of E1 through cellular compartments.  
Additionally, three N-linked glycosylation sites were found to be located on 
the E1 protein of all RuV strains, and these glycans contribute to adequate fold-
ing of E1 to exhibit suitable antigenic and immunogenic epitopes. In contrast, 
the E2 protein has N-linked glycosylation sites that are strain dependant.  
Furthermore, six nonoverlapping epitopes were found on the E1 protein, by 
the use of monoclonal antibodies. Some of these epitopes were associated with 
hemagglutination and neutralization. However, the E2 protein, found to be disul-
fide-linked to E1 in mature virion, is not well exposed and therefore less antigen-
ic [79, 81-84].  
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Penetration of RuV into the host cell takes place through endocytosis. The vi-
ral capsid protein releases the RuV RNA, into the cytoplasm of the host cell, by 
its conformation change from hydrophilic to hydrophobic that occurs at pH 5.0 
to 5.5. 
 
Within the infected host cell, the two viral RNA species play an important 
role during the replication (Figure 3.1). The 40S RuV genomic RNA acts as a 
messenger for the nonstructural proteins, but also as a template for the synthesis 
of its complement, the 40S negative-sense RNA strand. This RNA later serves as 
a template for the transcription of 40S RNA and 24S RNA. Newly formed 40S 
RNA is linked to the RuV capsid protein to form nucleocapsids. The 24S subge-
nomic RNA is translated into structural proteins [84].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of the translation and processing strategy of the RV 
non-structural and structural proteins. The RV genome comprises two long 
nonoverlapping ORFs, with the 5’ ORF coding for the ns proteins and the 3’ 
ORF coding for the structural proteins. A polyprotein precursor, p200, is trans-
lated from the 5’ ORF of the RV genomic RNA and undergoes cis cleavage to 
produce two non-structural proteins, p150 and p90. The locations of the putative 
amino acid motifs for methyltransferase (M), X motif, papain-like cysteine pro-
tease (P), helicase (H), and replicase (R) are indicated on the 5’ ORF. The RV 
structural proteins are synthesized from a 24S subgenomic RNA transcribed 
from the 3’ ORF. A polyprotein precursor, p100, is translated from the subge-
nomic RNA and undergoes several posttranslational modifications to ultimately 
produce the mature capsid (C), E2, and E1. Reproduced with permission grant-
ed from the American Society for Microbiology [84]. 
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1.3.2 Transmission, epidemiology and clinical presentation 
Humans are the only known host for RuV. Infected patients may transmit the 
virus, from 10 days before and 15 days after the eruption of the rash, by shed-
ding droplets of respiratory secretions produced by coughing. Also, secretions 
from children with congenital rubella syndrome (CRS) may transmit infection 
during the neonatal period to susceptible individuals [85, 86]. Infection occurs 
only once, since RuV immunity is lifelong. 
 
Rubella was not considered as an important disease until 1941, when Gregg 
linked it to congenital malformations (see section 1.3.3).  This infection was also 
known as the third disease in reference to other more important exanthematous 
diseases such as measles and scarlet fever.  
 
Before the introduction of the vaccine, rubella was reported to be more pre-
dominant in children of 5 to 9 years old with minor outbreaks taking place every 
6 to 9 years. Important outbreaks were occurring at intervals of up to 30 years. 
However, the introduction of the vaccine in 1969 modified the course of epi-
demics where no new large outbreaks presently occurs, and minor outbreaks are 
limited to communities where the index case is in close contact with susceptible 
individuals in schools, military camps, etc [86, 87].   
 
The WHO highlights the important reduction of rubella cases globally due to 
the increased vaccine coverage. In 2000, there were 670,894 rubella cases. This 
number decreased to 22,361 rubella cases in 2016, while the number of countries 
that introduced immunization with rubella-containing vaccine (RCV) increased 
from 102 in 2000, to 165 in 2016. Interestingly, the WHO region of the Ameri-
cas, and 33 of the 53 countries of the European region have successfully eradi-
cated rubella as of the 2016 report [88]. Other regions might also be able to 
eliminate rubella if the herd immunity could be maintained between 85% and 
91% [89].   
 
RuV is divided genetically into two clades, 1 and 2, based on an 8-10% dif-
ference at nucleotide level from a sequence of 739 nucleotides, (nt positions 
8,731 to 9,469) of the E1 protein coding region, as recommended by WHO. 
There are hitherto 13 reported genotypes where 10 (1A-1J) belong to clade 1 and 
the other 3 (2A-2C) to clade 2. Since 2010, only 4 genotypes are circulating with 
2B being the most widely distributed virus strain, followed by 1E, while 1G and 
1J are less frequently detected and more locally distributed. RuV strains of 1960, 
including viral strains contained in the vaccines, were of genotype 1A. Its occa-
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sional detection might be a result of laboratory contamination since this strain is 
frequently used in the laboratory [90, 91].  
 
Genotype 2B was reported globally whereas the genotype 1E was mainly 
found in eastern Asia and genotype 1G mainly in Africa. The rare findings of 
genotypes 1G and 1J might correspond to the under surveillance of rubella with-
in countries where they might be preponderant (Figure 3.2).  
 
Figure 3.2 Global Distribution of Rubella genotypes: 2010-2015. Source: WHO 
Rubella is often asymptomatic, but may manifest itself with mild symptoms 
such as fever, fatigue, and rash that starts on the face and disseminates over the 
whole body. Other signs are joint pain (a frequent symptom in adults), sore 
throat, and lymphadenopathies. Symptoms are more frequent and severe among 
female patients compared to males [84, 87, 92]. Rubella infection is associated 
with complications such as arthritis, encephalitis, hemorrhagic manifestations, 
and rarely orchitis, neuritis and the late syndrome of progressive panencephalitis. 
These complications are most severe in the fetus and fetal infection is associated 
with a high risk of severe congenital anomalies [93]. 
1.3.3 Congenital rubella syndrome 
This is a complication, which occurs in the fetus if RuV infects a pregnant 
woman during pregnancy. Infection during the first trimester of pregnancy is 
associated with the highest risk for the fetus to develop severe malformations 
[86]. In fact, the fetus has a 65%-85% risk of being affected by multiple con-
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genital malformations and/or spontaneous abortion if the infection occurs during 
the first 2 months of pregnancy. During the third month, the risk decreases to 
30%-35% and CRS might manifest itself with only one malformation such as 
heart defect or deafness. Infection during the fourth month is associated with 
10% risk of developing CRS, which then often is shown as deafness alone.  
 
CRS is linked to the accumulation of necrotic tissues, from chorionic epithe-
lium and endothelial cells, within the fetal circulation and organs. In turn, this 
leads to disturbance of mitosis and of development of precursor cells by inhibi-
tion of intracellular actin assembly; but the pathogenesis also involves upregu-
lated cytokines and interferon [89].  
 
Common manifestations of CRS are low birth weight and decreased head cir-
cumference, respiratory distress secondary to cardiac anomalies, cataract, hear-
ing impairment, splenomegaly, jaundice, thrombocytopenic purpura, depressed 
neonatal reflexes, developmental delay, and meningoencephalitis [85, 87, 92].  
1.3.4 Diagnosis  
Rubella is confirmed by detection of IgM antibodies from serum or oral flu-
ids, or of viral RNA isolated from nasopharyngeal secretions, oral fluids, urines 
or cataract tissue. A four-fold increase of rubella-specific IgG antibodies from 
serum samples collected during acute or convalescent phase of the disease, or the 
amplification of rubella virus RNA by RT-PCR confirms the diagnosis.  
 
Important consideration should be given to the time of sample collection. Ru-
bella-specific IgM positive results are often reported from most of the samples 
collected at the eruption of rash until 5 days after, while isolation and/or RNA 
detection of the virus is possible from the onset of the rash until at least 10 days 
postinfection. However, in the case of CRS, IgM specific to RuV, as well as vi-
ral RNA, may persist for months and thus be readily detected from samples col-
lected at a later period of the disease [89]. 
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1.3.5 Treatment and Prevention  
There is no antiviral treatment against RuV. Its management is based on 
treatment of symptoms.  
 
Prevention is done by administration of a live attenuated rubella virus vac-
cine, often given in combination (as RCV) with measles and mumps known as 
MMR vaccine. RCV is contraindicated in pregnant women and in immunosup-
pressed individuals, especially those with active HIV/AIDS [94]. Rubella-
specific IgG antibodies may test as false positive after infection with parvovirus 
or Epstein-Barr virus, or due to presence of Rh factor [89]. 
1.4 Chikungunya virus 
1.4.1 Virology: genes, proteins and replication  
Chikungunya virus is a mosquito-borne RNA virus that was isolated and re-
ported for the first time by Marion C. Robinson and W. H. R. Lumsden during 
an outbreak that occurred in Newala District of Tanzania in 1952 [95-97].  
 
This virus is a member of the Togaviridae family comprising the two genera 
Rubivirus of RuV species and Alphavirus to which, in addition to CHIKV, many 
other viral species belong. Among these are Sindbis virus, Semliki Forest virus, 
O’nyong-nyong virus (ONNV), Venezuelan Equine Encephalitis virus, Eastern 
Equine Encephalitis virus, Western Equine Encephalitis virus, Ross River virus, 
and several others.  
 
Alphaviruses including CHIKV have comparable structures and replication 
cycle processes. CHIKV is an enveloped, single-stranded, positive-sense RNA 
virus. Its genome contains around 12,000 nucleotides that encode four nonstruc-
turural proteins (nsP1, nsP2, nsP3, nsP4) that are translated from the 5’two-
thirds of the genomic RNA.  In addition, five structural proteins [98] C, E3, E2, 
6K, and E1, are translated from the 3’ one-third of the genomic RNA known as 
26S subgenomic, positive-sense RNA. This RNA is later transcribed from the 
negative-stranded intermediate RNA during the replication cycle of the virus. 
Thus, CHIKV genome is arranged as follows (Figure 4.1) 5’cap-nsP1-nsP2-
nsP3-nsP4-(junction region)-C-E3-E2-6K-E1-poly(A) 3’ [99, 100]. 
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Figure 4.1 Schematic presentation of the CHIKV genomic RNA, genes and translated pro-
teins. The scale indicated is in kilobases (kb), and presented here are the follow-
ing 5 regions: the 5’NTR of 76 nt, the ORF of 7,425 nt that translate non-
structural proteins, the junction region of 68 nt, and the ORF of 3,735 nt (or 26S 
subgenomic RNA) that translate structure proteins and the 3’NTR of 526 nt. Re-
produced and adapted from Journal of General Virology [100]. 
As for other Alphaviruses, the replication cycle of CHIKV (Figure 4.2) starts 
by virus infiltrating the host cell by endocytosis. The E1 peptide, which mediates 
virus-host cell membrane fusion, is exposed following conformational changes 
triggered by low pH of the endosome’s environment. Thereafter, the viral ge-
nome, from which two precursors of nsP translated from the viral mRNA under-
go cleavage to generate the four nsP (nsP1, nsP2, nsP3 and nsP4), is released. 
These nsP play an important role in the replication process of the virus. The 
nsP1 is involved in synthesis of negative-stranded viral RNA intermediate; nsP2 
displays RNA helicase function, as well as RNA triphosphatase and proteinase 
activities. This protein also plays a role in the viral shut-off of host cell transcrip-
tion. The nsP3 is a part of the replicase unit whereas nsP4 functions as the viral 
RNA polymerase. Together, these proteins form the viral replication complex 
that synthesizes the negative-stranded RNA intermediate which acts as template 
for the transcription of the subgenomic (26S) and genomic RNAs. The subge-
nomic RNA is then translated to the precursor of sP, the C-pE2-6K-E1, which is 
processed by an autoproteolytic serine protease thus releasing the capsid protein 
(C). The pE2 and E1 proteins associate in the Golgi and move to the plasma 
membrane where pE2 is cleaved into E2 involved in receptor binding, and E3, 
which mediates proper folding of pE2 and its association with E1. The recruit-
ment of the membrane-associated envelope glycoproteins to the encapsidated 
viral RNA form the virion, with an icosahedral core, which buds at the cell 
membrane [101].  
 
	
ORF	for	nsP	(7425	nt) ORF	for	sP	(3735	nt) 
   I-polyA 
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Figure 4.2 Replication cycle of alphaviruses [101]. Reproduced with permission requested 
from Springer Nature. 
1.4.2 Transmission, clinical presentation and epidemiology  
CHIKV is almost exclusively transmitted by mosquitoes. This vector main-
tains the sylvatic transmission cycle between non-human primates and mosqui-
toes, especially in Africa. A human-mosquito-human transmission cycle has 
been reported from Asia, the Indian Ocean, Africa, and from Europe. In addition 
to humans, other known hosts of CHIKV are monkeys, rodents and birds. Aedes 
aegypti mosquitoes were reported to be responsible for outbreaks within the 
tropical regions, while Aedes albopictus transmitted the virus in temperate areas. 
Mother-to-child or vertical transmission and blood transfusion were also report-
ed as potential mode of transmission of CHIKV [102-104].  
 
CHIKV is associated with a high rate of infection of a given population. 
Within a community affected by an outbreak, 10%-70% of individuals become 
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infected, with 50%-97% of these presenting clinical manifestations. In addition, 
high seroprevalence rates were recorded from areas that experienced different 
outbreaks: 38.2% positive subjects for specific IgM/IgG were found in the Indi-
an Ocean island of La Reunion, 75% in the island of Lamu in Kenya, 63% in 
Grande Comoro island and 90.4% in Suriname [105-109]. Clinical signs associ-
ated with CHIKV infection are polyarthalgia, which may persist for years, fever, 
transient macular or maculopapular rash found mainly on extremities, trunk and 
face, headache, and back pain [102]. CHIKV fever is also associated with severe 
complications such as neurological (encephalitis, Guillain-Barré Syndrome, etc), 
and haemorrhagical conditions such as clotting abnormalities or severe thrombo-
cytopenia. Other reported complications are conjunctivitis, myocarditis, pneu-
monia, nephritis, hepatitis, pancreatitis, etc. Severe infection may lead to death, 
often due to multiple organ failure [104]. 
 
CHIKV is endemic in tropical Africa, South-East Asia and in the Indian sub-
continent.  
Since its first recorded outbreak in the Newala District, Tanzania, in 1952, 
CHIKV outbreaks have expanded (Figure 4.3 A & B) to Senegal in 1996-1997, 
Malaysia in 1998-1999, the Central Africa Republic and the DRC in 1999-2000, 
to Indonesia in 2000-2003, and the Indian Ocean islands and India in 2004-2007. 
This latter outbreak, which occurred in a novel climate zone, was reported to be 
more severe and associated with a new vector species, Aedes albopictus, while 
previous outbreaks were vectored by Aedes aegypti. Three genotype groups of 
CHIKV, based on the sequencing of the envelope protein E1, have been de-
scribed. These are the east-central-south-African (ECSA) genotype, the Asian 
genotype and the west-African genotype [110, 111]. 
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Figure 4.3 Suggested dispersal of CHIKV from Africa to the Indian Ocean and Europe dur-
ing the past 20-50 years. Viral evolution and spread are represented according 
to recent phylogenetic studies. Different evolutionary lineages are identified us-
ing specific colours on the phylogenetic tree (A) and arrows with specific col-
ours on the global map (B) [112].  
A	
B	
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1.4.3 Diagnosis  
Laboratory analysis of serum samples from suspected patients, by serology 
and/or molecular methods, confirms the diagnosis of CHIKV infection. The RT-
PCR and virus culture might frequently be positive in samples that are collected 
between 3 and 10 days of the acute phase of the disease. Anti-CHIKV IgM anti-
bodies are detectable during the acute phase that lasts for 14 days from the onset 
of the disease, but might also be positive in samples collected up to 3 months 
from onset, while IgG antibodies may persist for years [113]. 
Other laboratory abnormalities observed may include lymphopenia, thrombo-
cytopenia, leucopenia, anemia, increased liver enzymes, creatinine and creati-
nine kinase, and hypocalcemia [104]. 
 
In May 2015, experts concluded on CHIKV case definition, based on differ-
ent phases of the disease. Four phases of CHIKV infection were described [114]:  
1. The acute clinical case is characterized by fever > 38.5°C and joint pain 
(usually incapacitating). These symptoms are often accompanied by ex-
anthema, myalgia, back pain, headache, or vomiting and diarrhea. The 
latter symptoms are common in children with acute onset of the disease. 
Furthermore, epidemiological criteria such as being a visitor or a resi-
dent in an area where local transmission of CHIKV has occurred during 
the preceding 15 days, or laboratory criterion of confirmation by PCR, 
serology or viral culture, should be fulfilled. 
2. Atypical clinical cases of CHIKV infection, confirmed by laboratory 
diagnostics, include other manifestations such as neurological, cardio-
vascular, dermatological, ophtalmological, hepatic, renal, respiratory, or 
hematological symptoms. 
3. Severe acute cases are defined as infected patients with laboratory-
confirmed CHIKV with dysfunction of at least one organ or system that 
threatens life and requires hospitalization. 
4. Suspected and confirmed chronic cases are defined as having a clinical 
diagnosis of CHIKV after 12 weeks following the onset of symptoms 
(presented continuously or recurrently) such as pain, rigidity, or edema. 
Its confirmation is laboratory based. 
1.4.4 Treatment and prevention  
As there is no antiviral treatment against CHIKV only symptoms can be 
treated. Disease-modifying anti-rheumatic drugs such as methotrexate, hy-
droxychloroquine or sulphasalazine might ameliorate severe chronic arthritis; 
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but treatment with anti-TNF-α antibodies was also associated with successful 
results. Several attempts in producing a vaccine and specific treatment agents are 
ongoing [115], but have hitherto not been successful. 
 
Prevention consists of implementation of vector control measures such as the 
use of mosquito repellents and cleaning of mosquito breeding sites [104, 109]. 
 
 
1.5 West Nile virus 
1.5.1 Virology: genes, proteins and replication  
West Nile virus (WNV) is a neurotropic mosquito-borne virus, which was re-
ported for the first time in 1937 from a febrile patient from the West Nile district 
in Uganda [116].  
 
WNV is a single-stranded, positive-sense RNA virus, which by taxonomy is 
placed in the Flavivirus genus within the Flaviviridae family. Other genera in 
this family are Pestivirus and Hepacivirus, the latter to which the important 
pathogen hepatitis C belongs. WNV is a member of the Japanese encephalitis 
virus serocomplex of flaviviruses which include Japanese encephalitis, Kunjin, 
Murray Valley encephalitis, St. Louis encephalitis, Kokobera, Alfuy, Stratford, 
Usutu and Koutango viruses. Other, more distantly related flaviviruses that are 
important human pathogens, are Dengue, yellow fever, and tick-borne encephali-
tis viruses (TBEV) [117].  
 
The viral genome, of around 11 kb with untranslated regions (UTR) at both 
ends, contains 10 genes (Figure 5.1) that encode one polyprotein subjected to 
cleavage into 3 structural proteins [the capsid (C), premembrane/membrane 
(prM/M) and envelope (E) proteins], and 7 nonstructural proteins (NS) known as 
the NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [118].  
 
Figure 5.1 WNV genome representation with one ORF encoding 3 structural and 7 non-
structural proteins [118].  
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During the replication process, the viral envelope (E) protein binds to the host 
cell receptors, and virions (Figure 5.2) enter the cytoplasm by receptor-mediated 
endocytosis. Virion particles are then transferred to the endosomes where they 
mature through a conformational change of the viral E protein dimer effected by 
the low pH within the endosomes. Fusion of viral particles with endosomal 
membrane triggers the release of WNV genomic RNA that initiates translation of 
polypeptides, and transcription into a complementary, negative-sense RNA in-
termediate, from which many new viral RNA molecules are replicated. These 
genomic viral RNA molecules are encapsidated by coupling with the C protein 
before budding into the endoplasmic reticulum while recruiting prM and E pro-
teins. These events occur within secluded replication complexes, which are 
formed from ER membranes, and involve upregulation of enzymes involved in 
cholesterol metabolism [119].  Immature virions are brought through the host 
secretory pathway by intracellular vesicles that fuse with the plasma membrane 
and release mature virions by exocytosis [120, 121]. 
 
 
 
 
 
 
 
 
Figure 5.2 Structure of WNV virion [118].  
1.5.2 Transmission, epidemiology and clinical presentation 
Culex mosquitoes transmit WNV while feeding on infected birds, which are 
considered as amplifying hosts. WNV is then passed on to susceptible verte-
brates including humans and horses as accidental dead-end hosts (Figure 5.3). 
Blood transfusion and organ transplant are also reported as a route for transmis-
sion, which in addition may occur from mother to child in utero or through 
breastfeeding [122]. Migratory birds were reported as transport vehicles of the 
virus from sub-Saharan Africa to Europe, America and beyond [123]. Some re-
ports also suggest that some ticks, namely Argasidae Argas and Ixodidae Hy-
alomma species, participate in transmission of WNV [124-126]. 
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Figure 5.3 WNV transmission cycle. Enzootic amplification of WNV occurs by birds and 
mosquitoes, by bird-to-bird transmission and through transmission between 
cofeeding mosquitoes. Vertical transmission by mosquitoes provides a mecha-
nism of virus overwintering. Humans and horses are regarded as accidental 
dead-end hosts. Human-to-human transmission may occur through blood trans-
fusion and organ transplant [118].  
WNV is distributed worldwide (Figure 5.4) with multiple viral lineages de-
fined according to nucleotide differences detected through genomic sequencing. 
Lineages 1 and 2 are the most commonly identified in Africa, where lineage 1 is 
frequent in central and northern Africa, Europe, Australia and Americas, and 
lineage 2 endemic in southern Africa, Madagascar, central Europe. Lineages 3 
and 4 are found in Russia, lineage 5 in India, and the less common lineages 6, 7 
and 8 respectively in Malaysia, Senegal and Spain. Virulence severity depends 
on the genotype. Lineages 1 and 2 were associated with epidemics within North 
America and Europe [124, 127-129].    
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Figure 5.4 Global distribution of WNV by country: Red-human cases or human seroposi-
tivity; Blue-non-human/mosquito cases or seropositivity; Gray-no data or no 
positive reported. Black lines represent worldwide distribution of the main WNV 
mosquito vectors, excluding areas of extreme climate denoted by dashed lines. 
Circled numbers indicate the reported presence of WNV lineages other than lin-
eage 1 in that specific area [118]. 
In most of the human cases, WNV infection is asymptomatic. Only 20% of 
infected individuals manifest clinical signs such as fever, headache, rash, muscle 
pain or weakness, joint pain or hepatitis. Neurological complications such as 
encephalitis, meningitis, Guillain-Barré syndrome occur in less than 1% and are 
associated with 10-20% of mortality, while survivors may develop severe neuro-
logical anomalies [130, 131]. Beside humans, horses are the most commonly 
infected mammal, where 90% of the affected animals develop neurological man-
ifestations with a mortality rate of 30% [132]. 
1.5.3 Diagnosis  
WNV infection is confirmed serologically by detection of IgM antibodies in 
serum and/or CSF using ELISA. IgM antibodies are often detected at the onset 
of neurological signs. Increased IgG antibodies against WNV measured from 
sera during the acute and convalescent phase are also indicative of WNV infec-
tion (Figure 5.5).  
IgM antibodies may, in some cases, be detected persistently until a year after 
onset; this is why IgM findings are not always indicative of an acute infection. 
Moreover, the WNV ELISA test does not discriminate IgM antibodies 
against WNV from those of St. Louis encephalitis or Japanese encephalitis vi-
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ruses. For confirmation, we refer to the neutralization test in form of the PRNT 
[124]. 
It is difficult to isolate WNV from the blood, or to detect viral RNA by RT-
PCR, as the viremia in humans and in horses is transient and of low quantity. 
However, in cases with encephalitis, findings of WNV RNA from the CSF have 
been reported, so RT-PCR performed on this body fluid may contribute to the 
diagnosis [133].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Viremia and antibody kinetics in West Nile virus infection [124]. 
1.5.4 Treatment and prevention  
At present there are no available treatments or vaccines against WNV. 
Vector control is currently the main means for prevention of WNV infection. 
Control is carried out by avoiding exposure to infected mosquitoes, by cleaning 
breeding sites, and by the use of larvicides, spraying pesticides, and insect repel-
lents. In endemic areas, screening of blood donation could be recommended us-
ing RT-PCR [122].  
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1.6 Zika virus 
1.6.1 History  
During a thorough search for viruses related to yellow fever virus, Zika virus 
(ZIKV) was originaly isolated in 1947 from the serum of a rhesus monkey from 
the Zika forest in Uganda. One year later an identical virus was isolated from 
homogenates of Aedes africanus mosquitoes from the same forest[134]. Thereaf-
ter, several regions reported their seroepidemiological data on ZIKV including, 
in Africa: the Central African Republic, Egypt, Gabon, Kenya, Nigeria, Senegal, 
Sierra Leone, Tanzania and Uganda, and in Asia: India, Indonesia, Malaysia, 
Pakistan, the Philippines, Thailand, and Vietnam. Before the outbreak of ZIKV 
on Yap island in the Federate States of Micronesia in 2007, ZIKV was seldom 
considered as a major pathogen as it was previously associated only with mild 
self-limiting febrile disease within those endemic areas [135]. However, during 
the 2007 outbreak, a majority of the population fell ill with high fever, rash, ar-
tritis, conjunctivitis, headache, edema and vomiting [136]. 
1.6.2 Virology: genes, proteins and replication 
ZIKV is a zoonotic mosquito-borne virus belonging to Flavivirus genus with-
in the Flaviviridae family. This virus was recently associated with major severe 
outbreaks and rapid global spread to non-endemic areas. The clinical presenta-
tion, which attracted high medical and media attention, was characterized by 
neurological complications and congenital malformations [137].  
 
Genetically, ZIKV carries a single-stranded, positive-sense, nonsegmented 
linear RNA genome of about 10,807 nucleotides (Figure 6.1.A). This genome 
contains a single ORF, which is flanked by two non-coding regions (NCR), and 
encodes a polyprotein of 3,423 amino acids. After translation, this polyprotein is 
cleaved into three structural proteins: C, prM, and E, and seven nonstructural 
proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5. Cleavage is brought 
about by the action of a combination of four proteases (Figure 6.1.B): the host 
signal peptidase, the viral NS3 serine protease, the host furin-like protease and 
an unknown host protease [135]. 
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Figure 6.1 Genome structure and polyprotein processing of ZIKV [135]. (A) Genome struc-
ture. The positive-sense genomic RNA of ZIKV is composed of a 5’NCR, a single 
long ORF, and a 3’NCR. (B) Polyprotein processing. The viral ORF encodes a 
3,423 amino-acid polyprotein, which is co- or post-translationally processed by 
host- and virus-encoded proteases into structural and non-structural proteins. 
Vertical black bars represent one or two transmembrane domains. Also indicat-
ed are the putative cleavage sites conserved among flaviviruses and the lengths 
of the cleavage products. Reproduced with permission from Springer Nature. 
The replication of ZIKV, as for many other flaviviruses, starts by attachment 
of virions to the host cell surface using adhesion factors such as lectin DC-SIGN 
and members of the phosphotidylserine receptor family. The viral E glycoprotein 
interacts with cellular receptors and triggers entry of the virus into the cell, by 
rapid clathrin-mediated endocytosis. In the endosomes, viral and cellular mem-
branes merge due to the acidic environment in this compartment. After fusion of 
membranes, virion releases the genomic RNA, which enters the cytosol and 
serves as mRNA, translating the polyprotein in association with the ER. Thereaf-
ter, the positive-sense RNA genome is transcribed into its complementary nega-
tive-sense RNA that in turn serves as a template for synthesis of many new 
positive-sense viral RNA genomes with involvement of different nonstructural 
proteins that also play a role in viral assembly. Viral glycoproteins prM and E 
form a heterodimer on ER membrane, for viral assembly, and drive the budding 
of the viral genomic RNA and C proteins into the ER lumen forming the imma-
ture virions. These particles move through the cellular secretory pathway during 
which the trans-Golgi-resident furin or furin-like protease cleaves prM into M 
protein and "pr" peptide leading to major structural rearrangements of the M and 
E proteins with formation of mature virions that are transported to the cell sur-
face and released by exocytosis [135]. 
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1.6.3 Transmission, clinical presentation and epidemiology  
ZIKV is transmitted to vertebrate hosts including humans by the bite of Aedes 
mosquito species, in particular Aedes albopictus and Aedes aegypti [138]. In 
contrast to WNV, humans can amplify ZIKV so that might maintain a human-to-
human transmission cycle as well (Figure 6.2). Non-vector transmission modes 
of ZIKV include blood transfusion, organ transplantation, sexual intercourse, 
and vertical transmission (from mother to child) [139, 140]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Transmission cycle of ZIKV [140].  
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Clinically, ZIKV infection is manifested by mild fever, headache, myalgia, 
arthralgia, conjunctivitis, prostatitis, hematospermia, subcutaneous bleeding and 
a rash, that often resolve within 3-7 days [141]. The disease may cause severe 
complications such as congenital malformations, in particular microcephaly 
(Figure 6.3), or neurologically by the autoinflammatory reaction Guillain-Barré 
syndrome [140]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 ZIKV and microcephaly. Source: CDC. 
From 1947 to 2007, though ZIKV infection was progressively expanding ge-
ographically (Figure 6.4), it was still considered as a benign disease with only 16 
human cases sporadically recorded and no related death reported. This figure 
might be underestimated since similar clinical manifestations are presented by 
dengue and/or chikungunya viruses’ infections, two viruses that are prevalent 
within the tropical region of Africa and Asia [142]. 
The new era of severe infection due to ZIKV was first recognized during one 
of the largest human outbreaks to be recognized; this was on the Pacific island of 
Yap in the Federated States of Micronesia where 73% of inhabitants older than 3 
years were found to be infected [136]. In 2015, Brazil reported 138 cases with 
neurological manifestations, of these 42% had a history of viral infection with 
55% showing symptoms consistent with Zika or dengue infection [137].   
 
Three genotypes of ZIKV were identified (Figure 6.5) with older strains be-
longing to the East African genotype, followed by the West African line, and, 
recently, the Asian genotype which has spread eastward through the Pacific re-
gion to the American continent. Most likely, some genetic alterations within the 
Asian genotype can explain the recent emergence and global spread of ZIKV. 
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Figure 6.4 Countries and territories showing historical time-line of Zika virus spread (1947 
- 2016). Source: WHO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Phylogenetic tree of Zika virus strains identified from Guatemala and Puerto Ri-
co in December 2015 (indicated in boldface) compared with reference isolates 
obtained from GenBank. Scale bar indicates number of nucleotide substitutions 
per site. Source: CDC. 
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1.6.4 Diagnosis  
ZIKV can be readily diagnosed by use of the ELISA that detects anti-ZIKV 
IgM antibodies in serum or other body fluids, including saliva. From reports of 
other flaviviruses, IgM may be detected within 10 days, and up to 2 months after 
the onset of clinical signs. However, ELISA tests are not always reliable due to 
cross-reactivity with other flaviviruses, and the plaque reduction neutralization 
test (PRNT) is sometimes used to confirm the specificity of ZIKV-IgM signals 
[143]. 
Due to the problems of serological specificity, the diagnosis of ZIKV often 
relies on RT-PCR methods, which can detect the viral RNA within 1 week of the 
onset of clinical manifestations [143]. Suitable sample fluids are serum and 
plasma, whole blood, urine and amniotic fluid. 
1.6.5 Treatment and prevention  
At present, ZIKV treatment is based on management of symptoms only, as no 
ZIKV vaccine or licensed antivirals are available for prevention or treatment. In 
parallel with the situation for several other flaviviruses, research is ongoing to-
wards development of vaccines and antivirals drugs against ZIKV [144-146]. 
 
Prevention of ZIKV infection consists mostly of mosquito vector control by 
eliminating breeding sites by distribution of larvicides, by the use of mosquito 
repellents and bed nets. Human-to-human spread can be reduced by avoiding 
unprotected sex with an infected partner, but also by preventing exposure of the 
pregnant women to ZIKV [147]. 
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1.7 Tick-borne encephalitis virus 
1.7.1 Virology: genes, proteins and replication  
Tick-borne encephalitis, as a clinical entity, was reported for the first time in 
Europe in 1931 from an outbreak of “acute epidemic serous meningitis” in 
southeast Austria, and the virus was first isolated in the former Soviet Union in 
Russia in 1937 [148, 149].  
 
Although TBEV belongs to the flaviviruses, as a tick-borne virus it forms a 
separate genogroup together with viruses such as Omsk hemorrhagic fever virus 
(OHFV), Powassan virus, Alkhurma virus, and louping ill virus. In general, the 
group of tick-borne flaviviruses has been given less scientific attention as com-
pared to the mosquito-borne flaviviruses [150].  
 
The TBEV genome, as that of ZIKV, consists of a linear positive-sense, sin-
gle-stranded RNA with only one ORF encoding one polyprotein that is cleaved 
into three structural proteins, the envelope (E), the capsid (C), the membrane 
(M), and seven nonstructural proteins [150]. 
 
Replication of the virus starts by virus attachment and penetration into the 
host cell through receptor-mediated endocytosis where the viral E protein attach-
es onto host cell receptors such as heparan sulphate and other glycosaminogly-
cans, which are commonly found on many cell types of vertebrates and ticks 
[151]. The fusion of the virus-containing vesicle with the endosomes, within an 
acidic environment, triggers a conformational change of viral envelope E protein 
inducing the release of the viral nucleocapsid into the cytoplasm of the host cell. 
Thereafter, the viral RNA is translated directly by host cell ribosomes to viral 
polyproteins that are cleaved by viral serine protease and cellular proteases into 
the respective viral proteins. The transcribed negative-sense viral RNA serves as 
a template for transcription of new copies of the positive-sense viral RNA ge-
nome. These positive-sense RNA molecules are encoated by viral capsid pro-
teins to form nucleocapsids that bud into the ER lumen. Here, the nucleocapsids 
are covered by a bilayer lipid membrane with prM and E protein molecules in-
serted, forming immature virions. These virions are transported to the Golgi ves-
icles through the secretory pathway where they mature with cleavage of the prM 
protein by the host cell protease furin. Fusion of mature virions with plasma 
membrane of the host cell triggers the release of the virus through exocytosis 
[152, 153]. 
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1.7.2 Transmission, clinical presentation and epidemiology 
TBEV is usually transmitted by ticks of the Ixodideae family. Furthermore, 
unpasteurized and virus-contaminated diary products such as raw milk and 
cheese from goats and sheep could infect susceptible individuals through the 
alimentary tract [154-156]. The life cycle of TBEV is normaly maintained by 
hard ticks (Ixodes ricinus and Ixodes persulcatus mainly) functioning as vectors, 
and by small rodents (Myodes Glareolus), hares and deer acting as reservoirs 
(Figure 7.1). Humans and domestic animals (cattle, goat, and sheep) are consid-
ered as dead-end hosts that are unable to transmit the virus due to their inability 
to develop a high grade of viremia [157]. Migratory birds have been suggested 
as transporters of the virus over large distances, most likely by carrying TBEV-
infected ticks into new areas, where they can expand far from their original en-
demic foci [158]. 
 
 
 
 
Figure 7.1 Developmental stages of Ixodes ricinus (Ixodes spp.) with TBEV transmission 
routes [159]. Reproduced with permission requested from Springer Nature. 
Most often TBEV infection is asymptomatic. However, when the infection 
does present with clinical signs and symptoms, these are typically of a neurolog-
ical character such as encephalitis, meningitis or meningo-encephalitis with or 
without paralysis, and other neurological sequelae [160]. Common clinical 
symptoms are chills, headache, nausea, vomiting, muscle pain, sore throat, 
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blurred vision, photophobia, poor concentration, tremor, etc [154, 156]. The viral 
subtype may influence the severity of TBE. For the European subtype (TBEV-
Eu), up to 10% of patients can develop neurological sequelae, with a mortality 
rate of 0.5-2%, as compared to the more virulent Siberian subtype (TBEV-Sib) 
for which the infection may have a longer duration and where 2-3% of patients 
die. The Far-Eastern subtype (TBEV-Fe) is reported to be even more severe, 
with a case fatality rate of up to 40% and high rate of neurological sequelae in 
survivors [161]. However, it should be mentioned here that more recent studies 
from China and Japan report much lower mortalities of this subtype [162]. 
 
These three subtypes manifest a low variation of their respective amino acid 
sequence, with 2.2% variability within subtypes, and up to 5.6% between sub-
types when sequencing the gene that encodes the viral envelope E glycoprotein. 
This protein induces a high amount of neutralizing antibodies, as compared to 
other viral proteins such as NS1. The protective IgG response of the host is ac-
tive against all TBEV subtypes (genotypes), thereby classifying TBEV as mono-
serotype virus [152, 163]. 
 
TBEV is reported to be endemic in central, eastern and northern Europe and 
Asia (Figure 7.2.A). Most TBEV cases occur during the period of activity of 
ticks [164], often from April to November. The three main genetic subtypes (as 
mentioned above), which usually are based on envelope protein E sequencing, 
are each more or less prevalent in different endemic foci. However, multiple 
subtypes may sometimes be detected within an individual endemic area. The 
TBEV-Fe subtype is predominantly found in far-eastern Asia and Japan, while 
the TBEV-Eu subtype is highly prevalent in Europe. In addition, a third geno-
type (TBEV-Sib) is endemic in Siberia, the Baltics, and northern Finland (Figure 
7.2.B). Two additional genotypes were also identified in eastern Siberia, but too 
few sequences have been presented to allow a characterization of these viruses 
as possible new subtypes. The future taxonomy may well be based on numerical 
genotypes instead of geographical names, since a more mosaic pattern of spread 
can be anticipated. For example, a recent report describes the finding of TBE-Eu 
in several locations on the Korean peninsula [162]. An example of such a numer-
ical classifications is given in Figure 7.2.B.  
Cases decreased drastically in Europe where 12,733 were recorded in 1996 
and only 2,876 in 2016 within all the European regions [161, 165-167].  
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Figure 7.2 A. The “TBE belt” (prevalence of TBE viruses) in ticks, animals, and hu-
mans [159]. B. Geographical distribution of TBEV genotypes [167]. Repro-
duced with permission from the Journal of Medical Virology. 
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1.7.3 Diagnosis  
Diagnosis of TBE infection is demonstrated serologically through ELISA by 
detection of IgM and IgG antibodies from serum and CSF samples [156, 168]. 
IgM antibodies may be detected for months whereas IgG antibodies can prevail 
for a long time and may confer lifelong immunity [169]. 
 
To overcome diagnostic bias due to extensive cross-reactivity among fla-
viviruses, the ELISA tests can be confirmed by a neutralization test [170, 171].  
 
Viral RNA can also be detected by RT-PCR in blood, urine or CSF collected 
mainly during the first viremic period before seroconversion and occurrence of 
CNS inflammation. If PCR sampling is delayed, the method has less diagnostic 
value [156, 168, 169, 172]. 
1.7.4 Treatment and prevention  
There is no antiviral treatment against TBEV. Thus, patient care is based on 
symptomatic therapeutics. 
Post-exposure prophylaxis by immunoglobulins containing gamma globulin 
against TBEV scheduled within 96 hrs of tick bite was discouraged due to unre-
liable protection and to reports about induction of a more severe course of the 
disease in children [173].  
 
The prevention instead focuses on promoting the awareness of the risk of in-
fection from tick bites in TBEV-infested regions, and vaccination of subjects 
living in or travelling to endemic areas is encouraged. Two killed vaccines, both 
of which are based on the TBEV-Eu subtype of viruses, are commercially avail-
able for children and adults in Europe: FSME-Immun® approved by the Europe-
an Medicine Agency since 1976 and Encepur® from 1991. Both vaccines were 
found to confer 100% seroconversion with minimal adverse reactions. After in-
troduction of general vaccination in Austria, a sharp decline in the TBE inci-
dence was reported [174]. The vaccine is scheduled in 3 doses, from Day 0, after 
1-3 months, and the third after 9-12 months, with boosters recommended every 
3-5 years. Similarly, two Russian vaccines, based on the TBEV-Fe subtype, 
TBE-Moscow and EnceVir, are mostly used in Russia and China [149, 155]. 
However, a cautionary warning on the efficacy of killed TBEV vaccines should 
be raised, based on recent reports of a substantial number of TBE cases with 
vaccine break-through infection [175] 
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2. Aims 
2.1 General aim 
To utilize seroepidemiology in Rwanda to control for immunity to emerging 
arboviral infections, and to exanthematous viral infections that can be prevented 
by vaccination programs. 
2.2 Specific aims  
Paper I 
To assess the seroprevalence of MeV in Rwanda, and to relate these findings to 
the reported vaccine coverage and to the incidence of clinical measles in the 
country.   
Paper II 
To investigate, through seroepidemiology, the susceptibility of Rwandans to two 
viruses that cause congenital lesions: RuV, a vaccine-preventable infection, and 
ZIKV, an emerging flavivirus. 
Paper III 
To assess the seroprevalence of CHIKV and WNV in Rwandan blood donors, 
and the prevalence of the mosquito vectors used by respective viruses. 
Paper IV 
To analyse linear epitopes of sera that were cross-reactive between WNV and 
TBEV among Rwandan and Swedish blood donors. 
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3. Materials and Methods  
3.1 Study design and samples collection 
The study was designed as a sandwich PhD project where half of the time was 
dedicated to fieldwork in Rwanda and the other half to laboratory analyses and 
PhD courses in Sweden (Figure 8.1) 
 
 
 
 
 
 
 
Figure 8.1 Study project design representing the map of Rwanda and of Sweden showing 
Gothenburg 
The fieldwork consisted of collection of plasma samples from blood donors from 
all four provinces of Rwanda, and from the City of Kigali. 
The National Center for Blood Transfusion (NCBT) in Rwanda comprises 5 
regional centers: Kigali, Rwamagana, Huye, Musanze and Karongi. Each of the-
Fieldwork 
Lab work and 
courses 
Sandwich 
mode 
Rwanda	
 50   3 .  MATERIALS AND METHODS 	
 
se regional centers has a blood collection center, in addition to the 548 mobile 
collection sites that are active nationwide [176]. 
Recruitment of blood donors was conducted from March to October 2015, in 
line with the policy of the Rwanda National Center for Blood transfusion [177]. 
The following data were recorded from the donors: age, sex, and residence. 
Blood samples of 3-5 ml whole blood in EDTA tubes were collected from each 
participant. Samples were then transported to the corresponding regional center 
for blood transfusion where they were centrifuged for separation of 0.5 to 1.5 ml 
of plasma, which was stored directly at -20oC. All plasma samples from each 
region were then transferred to the Rwanda Military Hospital, located in Kigali 
City, and kept frozen at -80oC until shipment to Sweden. 
 
Serum samples from Swedish blood donors were anonymous, and characterized 
by age and sex only. These samples were also collected in September 2015, and 
stored frozen at -20oC in the clinical laboratory of the Microbiology Department 
(ML) at Sahlgrenska University Hospital (SUH). These serum samples were 
used for comparative seroprevalence studies on the vaccine-preventable viruses 
MeV and RuV, and also as negative control for IgG reactivity to the mosquito-
borne viruses CHIKV, ZIKV and WNV.  
 
Additional samples of serum and CSF from Swedish TBEV-positive patients 
were retrieved from storage at -20oC, in the ML at SUH. 
Paper I 
Data on IgG reactivity to MeV presented here were derived from serological 
analysis of 516 plasma and 215 serum samples from Rwandan and Swedish do-
nors, respectively. Rwandan samples were collected according to the availability 
of measles ELISA kits, but also to regional representation in Rwanda. In addi-
tion, data on suspected cases of measles recorded from June 2010 to June 2011 
were included. Results from analyses of MeV IgM (n= 544 plasma samples) and 
from MeV RT-PCR (n=31 nasopharyngeal swabs) were provided by the Rwan-
dan national measles surveillance programme. WHO granted the permission to 
include data on measles vaccine coverage and the measles incidence reported by 
Rwanda and neighbouring countries for the period between 1980 and 2014.  
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Paper II 
Seroprevalences of ZIKV and RuV IgG antibodies were tested on 874 plasma 
samples and 215 serum samples from Rwandan and Swedish donors, respective-
ly. The anti-Zika IgG positive serum samples were analysed by real-time reverse 
transcription polymerase chain reaction (RT-qPCR) to detect ZIKV RNA. 
Paper III 
IgG to CHIKV and WNV were tested in 874 plasma and 199 sera from Rwandan 
and Swedish donors, respectively. Some Swedish samples with low volume were 
not tested. To investigate the probable cross-reactivity between WNV and 
TBEV, all samples that were positive for anti-WNV IgG antibodies among the 
Rwandan donors (n=91) and all of the samples from the 199 Swedish donors 
were tested for IgG reactivity to TBEV. Additional data included distribution of 
mosquito vectors, estimated from data on the 2012 assessment of yellow fever 
virus circulation in Rwanda. 
Paper IV 
In follow-up assessment of data derived from investigations of seroprevalence to 
CHIKV and WNV described in paper III, all sera from Swedish donors that were 
seropositive to WNV (n=28) were tested with the TBEV plaque reduction neu-
tralization test (PRNT). However, Rwandan plasma samples could not be tested 
for TBEV neutralization activity with the PRNT for methodological reasons. 
Being a cell-based assay, the PRNT does not function with plasma samples due 
to the cell damage induced by the added anti-coagulants (EDTA). Additionally, 
serum samples with anti-TBEV IgM antibodies positive from Swedish patients 
(n=58) were also assayed for anti-WNV IgG antibodies. 
  
For analysis of TBEV and WNV linear IgG epitopes on pepscan, samples were 
pooled as follow: 
1. Pool 1 was prepared from 6 sera from confirmed Swedish TBE patients 
with high WNV IgG. 
2. Pool 2 was prepared from 3 sera from Swedish blood donors with high 
WNV IgG results but negative in PRNT for TBEV antibodies. 
3. Pool 3 contained 6 sera from Swedish blood donors with high WNV 
IgG and high TBEV IgG values, which also were positive for TBEV 
antibodies on PRNT. 
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4. Pool 4 included plasma from six Rwandan blood donors with high IgG 
results on WNV ELISA, as well as on TBEV ELISA. 
5. Pool 5 was prepared from 4 CSF samples from Swedish patients with a 
confirmed diagnosis of TBE. 
3.2 Analysis of samples 
 
Serological and real-time RT-PCR studies of collected blood donor samples 
were carried out in the ML at SUH (Figure 8.2). Pepscan analysis of se-
rum/plasma for IgG antibodies to linear epitopes of WNV and TBEV was car-
ried out at PEPperPRINT GmbH, Heidelberg, Germany. The plaque reduction 
neutralization test for TBEV neutralizing antibodies was carried out at the Public 
Health Agency of Sweden, Stockholm. 
 
 
Figure 8.2 Analysis of Rwandan and Swedish blood donor’s samples 
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3.2.1 Serological analysis 
Seroprevalence results were based mainly on ELISA assay against the six RNA 
viruses tested, MeV, RuV, ZIKV, WNV, CHIKV and TBEV. Each reaction plate 
contained plasma samples from Rwandan participants as well as serum samples 
from Swedish blood donors or patients (Figure 8.2).  
 
ELISA assay techniques are based on binding antibodies onto antigens coated on 
the wells of an ELISA microtiter plate. After rinsing, a secondary antibody con-
jugated to an enzyme is added, which binds to the specific antibody present on 
the antigen. Thereafter, the addition of a substrate produces a colour change, 
which occurs in the presence of the enzymatic activity of the bound conjugate. 
Positive and negative reactions, in relation to controls, are determined by optical 
density (OD) values obtained by the spectrophotometer (Figure 8.3). 
 
 
Figure 8.3 Serological testing techniques using indirect ELISA [178].  
3.2.1.1 MeV ELISA for determination of IgG and IgM antibodies 
 
To assess seroprevalence of MeV IgG antibodies in blood donor samples, sera 
and plasma were analysed using the Enzygnostic Anti-MeV/IgG Enzyme immu-
noassay kit (Siemens Healthcare Diagnostic Products GmbH, Mar-
burg/Germany) according to the manufacturer’s instructions. 
Participants were divided into two groups, the first of those aged below 35 years 
and the second 35 years and above, to compare the seroprevalence before and 
after the introduction of the measles vaccine in Rwanda   
 
Data on measles cases were derived from the Rwanda National registry on mea-
sles and rubella surveillance within the WHO global measles and rubella lobora-
tory network. In Rwanda, measles cases were diagnosed using a commercial 
IgM ELISA kit from the same company as above, when serum samples were 
available for examination.  
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3.2.1.2 RuV and ZIKV IgG ELISA 
  
IgG antibodies to RuV and ZIKV (targeting NS1) were measured using com-
mercial ELISA kits provided by ARCHITECT Rubella IgG Abbott Sligo Ire-
land, and EUROIMMUN Medizinische Labordiagnostika AG Germany, 
respectively. The Rwandan and Swedish samples examined were analysed as 
described in the instructions provided by the manufacturers.   
 
 
3.2.1.3 WNV and TBEV IgG ELISA 
 
Anti-IgG antibodies to WNV were analysed using a complete commercial sero-
logical kit supplied by FOCUS Diagnostics (Cypress, California 90630 USA), 
according to instructions from the manufacturer. 
Following the relatively unexpected high seroprevalence to WNV detected in 
Swedish blood donors, and the known problem of cross-reactivity between fla-
viviruses [179-183], we compared these WNV IgG findings in blood donors 
from Rwanda and Sweden with the seroprevalence of TBEV IgG in the two 
groups. To this end, we utilized the commercial Enzygnost Anti-TBEV IgG 
ELISA kit (Siemens Healthcare AB, Upplands Väsby, Sweden) to measure anti-
TBEV IgG, according to the instructions from the manufacturer. 
 
 
3.2.1.4 TBEV neutralization test 
 
All Swedish sera testing positive for WNV IgG in the ELISA assay were tested, 
in the two dilutions 1/5 and 1/20, for cross-reactivity with TBEV, by plaque re-
duction neutralization test at the Public Health Agency of Sweden, Stockholm. 
 
 
3.2.1.5 CHIKV IgG ELISA 
  
The seroprevalence of IgG antibodies to CHIKV was assessed using an in-house 
viral recombinant envelope protein (p62-E1) Ag (batch no. 120820) 1 mg/ml 
(kindly supplied by Peter Liljeström, KI), and a two-phase analysis by ELISA 
was performed as described below.  
 
Initially, we determined the optimal dilution of the CHIKV Ag solution, and of 
positive controls, and human plasma and serum samples. Different concentra-
tions, by serial dilution of the antigen, were tested using as positive control a 
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serum from a cynomolgus macaque immunized with a DNA-launched CHIKV 
replicon encoding the CHIKV E protein, and boosted with recombinant modified 
vaccinia Ankara strain expressing the same antigen [115]. Horseradish peroxi-
dase (HRP) mouse anti-monkey IgG conjugate was used as secondary antibody. 
The concentration of 0.25 µg/ml of the CHIKV antigen, a 1:200 dilution of the 
monkey positive control serum, and a 1:200 dilution of human plasma were 
found as optimal in order to provide the best signal/background ratio.  
 
Thereafter, we assayed IgG seroprevalences using the CHIKV ELISA test on 
Rwandan and Swedish blood donor samples. Samples were screened in dupli-
cate, at a dilution of 1:200. The positive control was a human plasma sample 
from a Mozambique patient who was found to be positive for CHIKV RNA on 
RT-PCR (sample provided generously by Dr Kerstin Falk from the Public 
Health Agency of Sweden, Stockholm). An HRP labeled anti-human IgG conju-
gate prepared in goat (Jackson ImmunoResearch Europe Ltd, UK) was used as 
secondary antibody.  
 
Positive results were defined as values above the cut-off point determined by the 
first point of OD, which had the lowest number of samples (nadir), observed on 
a drawn chart based on the OD values of all samples (Supp. Figure Paper III). 
Thus, OD values greater than 0.45 were considered as positive. 
 
We compared our findings from this novel assay using a serological commercial 
ELISA test (Ab177835 Anti-Chikungunya virus IgG human ELISA kit, Abcam, 
not intended for diagnostic use) on 9 strong positive, 9 intermediate positive, 9 
weak positive, 8 negative CHIKV from Rwandan plasma samples, and on 9 
Swedish CHIKV samples.   
3.2.2 Real-time RT-PCR for Zika virus RNA 
To investigate for a possible active infection of ZIKV, the ZIKV IgG positive 
samples (all collected from the Rwandan donors) were tested with reat-time RT-
PCR at the ML at SUH. 
Nucleic acids were extracted using the NucliSENS easyMAG instrument (bio-
Mérieux, Marcy-l’Étoile, France) following the manufacturer’s instructions. 
Thereafter, extracted nucleic acids were tested for ZIKV RNA by an in-house 
TaqMan real-time RT-PCR using specific primers:  
(zikaFP1 5′-CACCAATTATGGACACCGAAG-3′,  
zikaFP2 5′-CTCACCAATTATGGACACAGAAG-3′ and  
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zikaRP 5′-TCACCCAATCAAAGCCTGAG-3′)  
and the BHQ1 labeled probe:  
(zikaPCH 5′FAM-TCCAGGCTCTCTCTGGGACTTCC-3′-BHQ1) that target 
the relatively conserved NS3 region of the viral genome.  
3.2.3 RT-PCR for measles virus RNA 
Measles virus RNA was amplified in RT-PCR carried out at Uganda Virus Re-
seach Institute in Kampala, where the Qiagen OneStep RT-PCR kit was used 
with two primers targeting the 3’ region of the nucleoprotein gene (measles gen-
otyping kit v2.0 CDC, Atlanta):  
forward primer (MeV216) 5’TGG AGC TAT GCC ATG GGA GT 3’ and  
reverse primer (MeV214) 5’TAA CAA TGA TGG AGG GTA GG 3’.  
These target primers were previously described elsewhere [184]. 
The genotyping, based on nucleotide sequencing of the 634 base pairs product 
followed by BLAST homology analysis, was performed at Center for Vaccines 
and Immunology in Johannesburg, South Africa. 
 
3.3 Statistical analysis 
Data were recorded and analysed using the IBM SPSS Statistics vs. 20 (IBM 
Corp., Armonk, NY).  
Seroprevalence to different viruses were presented as number (n) and percentage 
(%). Comparison of seroprevalences between Rwandan and Swedish donors was 
evaluated by the Pearson’s Chi-squared test for independence, while the mean 
IgG OD values were compared using the Student’s t-test for two independent 
samples. Significant results were defined by a p value less than 0.05. 
  
3.4 Ethical considerations 
This research project was reviewed and approved by the National Heath Re-
search Committee (Ref: NHRC/2014/PROT/0196) of the RBC and the Ministry 
of Health in Kigali. 
University Research Ethics committees at Kigali University Teaching Hospital 
(Ref: EC/CHUK/029/12, and Ref.: EC/CHUK/216/2016) and at Rwanda Mili-
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tary Hospital (Ref: 002/010/2014) reviewed and cleared the study project. Suffi-
cient information about the study was provided to all participants and those who 
accepted to sign the consent form were enrolled.   
 
The Swedish blood donors were analysed anonymously and results could not be 
traced back to individuals. According to Swedish rules, ethical permission is not 
required in this context. 
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4. Results and Discussion 
4.1 Paper I 
 
This paper describes the seroprevalence of measles from 516 Rwandan and 215 
Swedish blood donors, and outbreaks of measles infections during 2010-2011 in 
Rwanda. Finally, WHO data on vaccine coverage against measles in Rwanda 
from 1980-2014 in comparison to its neighbouring countries are included. This 
is the first seroprevalence study assessing the performance of the immunization 
program in Rwanda. 
4.1.1 Measles seroprevalence  
The seroprevalence to MeV was found to be 71.5% among Rwandan blood do-
nors, as compared to 92.6% among the Swedish donors (table 8.1). Rwandan 
donors were divided in two age groups, those born after the introduction of the 
measles vaccine (in 1980), i.e. <35 years old and the older subjects born before 
1980 (≥ 35 years old). The same age groups were valid for Swedish donors as 
well. When assessing the influence of age, younger Rwandans (< 35 years of 
age) showed a seroprevalence to MeV of 64.8% while their older counterparts 
presented a seroprevalence of 90.4%. Younger Swedish donors presented a 
slightly lower seroprevalence to measles of 88.9%, when compared to older 
Swedish subjects (≥ 35 years) who had a seroprevalence of 94.1%. As an indi-
rect estimation of antibody quantities, the mean MeV IgG OD value was 0.68 
from younger Rwandan donors, as compared to 1.2 from the older subjects. Sim-
ilarly, younger Swedish donors showed a lower mean of MeV IgG OD value 
(0.69) when compared with their older counterparts, who had a mean OD value 
of 1.65. The most probable explanation of these findings was that the older sub-
jects from both countries had been naturally infected, while a large proportion of 
the younger individuals showed immunity after vaccination only. 
 
The lower measles seroprevalence among blood donors in Rwanda of 71.5% in 
comparison to the Swedish donors (92.6%), found in our study, might be influ-
enced by the fact that only one dose of measles vaccine was administered in 
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Rwanda from 1980 until 2013, as compared to the two doses given in Sweden 
since 1982. Furthermore, Rwandan donors were younger in general (mean age: 
29.1 years) in comparison to Swedish donors with a mean age of 44.3 years. The 
booster that was introduced in the Rwandan program of immunization as a se-
cond dose of measles vaccine from 2014 might improve both the seroprevalence 
and the strength of immunity as indicated by the OD values. 
 
Table 8.1 Measles seroprevalence and mean age of Rwandan and Swedish donors 
  Rwandan (n=516)    Swedish (n=215) 
  <35 ≥35 Total  <35 ≥35 Total 
Positive 247 (64.8%) 122 (90.4%) 369 (71.5%)  56 (88.9%) 143 (94.1%) 199 (92.6%) 
Negative 94 (24.7%) 10 (7.4%) 104 (20.2%)  4 (6.3%) 7 (4.6%) 11 (5.1%) 
Equivocal 40 (10.5%) 3 (2.2%) 43 (8.3%)  3 (4.8%) 2 (1.3%) 5 (2.3%) 
Mean MeV IgG OD 0.68 (0.62-0.74)  1.20 (1.1-1.3)  0.85 (0.79-0.91)  0.69 (0.58-0.80)  1.65 (1.54-1.76) 1.38 (1.28-1.48) 
Mean age (Yr (range)) 29.1 (18-62)  44.3 (18-75) 
 
4.1.2 Measles incidence  
Out of 544 suspected cases of measles collected in Rwanda during the 2010-
2011 surveillance of measles, 76 cases were confirmed by IgM positive results 
on ELISA (Table 8.2). Two age groups of these suspected cases were consid-
ered, based on the definition of pediatric (<16 years) and adult (≥ 16 years) age 
in Rwanda. Of the 544 suspected cases, 91.4% were < 16 years old, from whom 
58 cases (11.7%) were IgM positive, while 8.6% were ≥ 16 years old with 18 
cases (38.3%) being IgM positive. The higher proportion of confirmed measles 
cases within the older group might be explained by the possibility that a higher 
proportion of infections in young children were presenting clinical manifesta-
tions similar to those of measles, as compared to presentation in adults.  
Of the seventy-six IgM positive measles cases, only 16 (21%) were aged ≥ 16 
years old while 60 (79%) were < 16 years. This confirms that measles is still a 
childhood infection in Rwanda. 
 
During the same measles surveillance period, 31 nasopharyngeal samples were 
collected from suspected cases, and 21 (67.7%) of these samples were PCR posi-
tive. Genotyping revealed that all measles positive samples from Rusizi and 
Nyarugenge districts were of the B3 subtype, and further phylogenetic analysis 
suggested that this strain might have been imported from DRC. Further support 
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for this hypothesis is the incidence map of patients positive for IgM against mea-
sles [185]. As shown there (paper I, figure 2), a large majority of positive sub-
jects were found in regions bordering DRC and Burundi. 
 
Table 8.2 Suspected and confirmed measles cases in Rwanda 
  Suspected measles cases (n (%)) IgM-positive (n (%)) Positive PCR results Genotype 
Age     
<16 years 497 (91.4) 58 (76.3)*   
≥16 years 47 (8.6) 18 (23.7)**   
Total 544 76   
     NPH samples 31  21 (67.7%) B3 
*   Of the younger subjects 58/497 (11.7%) were IgM positive 
** Of the older subjects 18/47 (38.3%) were IgM positive 
 
As a possible explanation of the presently low incidence of measles cases in 
Rwanda despite our findings of a low seroprevalence, vaccine coverage has been 
kept high during the last decades and has also included immunization of refugees 
[186, 187]. The reported mean vaccine coverage rate was > 80% for the last 30 
years (since 1988), except in 1994 (year of genocide) where everything was de-
stroyed including healthcare facilities and human resources, and a record low 
coverage of < 25% was recorded [188-190]. The incidence of measles varied 
accordingly. Since 1988, measles incidence was below 10,000 cases, except dur-
ing the war period where high incidence was recorded: 17,429 cases in 1992 and 
28,874 cases in 1995 [188]. Even though the vaccine coverage is currently high, 
outbreaks of measles can still be anticipated in Rwanda in the future, given that 
almost 30% of the donors tested here were non-immune. 
 
Compared to its neighbouring countries (table 8.3) during the period of 2003 to 
2014, the reported measles vaccine coverage was high and the number of mea-
sles cases was low in Rwanda. 
However, the few unvaccinated individuals and the non-responders to the vac-
cine in Rwanda might still be susceptible to imported measles [191, 192], as 
indigenous measles strains might be eradicated by the sustained high measles 
vaccine coverage [193, 194]. 
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Table 8.3 Comparison of measles vaccine coverage and of measles cases in Rwanda and 
its bordering countries during 2003 to 2014, based on data from WHO.  Mean 
values for the period are presented. 
 
The high number of measles cases reported by DRC and Uganda might be ex-
plained by their vast countries, in addition to their relatively low vaccine cover-
age rates. In Tanzania, the higher incidence of measles, despite similar vaccine 
coverage rate as Rwanda, may be explained (at least partly) by having a five 
times larger population. Interestingly, the DRC and Uganda are also improving 
their vaccination coverage rate with a mean of 89.8% and 92% respectively over 
the last 5 years (from 2013 to 2017) [188]. 
 
To conclude, the higher seroprevalence to MeV and the higher mean OD values 
to this virus observed in older donors as compared to the younger donors of both 
countries might be explained by the stronger immune response induced by natu-
ral infection as compared to that after vaccination. The finding that Swedish do-
nors showed higher seroprevalence and higher OD values in comparison to their 
Rwandan counterparts is most likely explained by the use of only one dose of 
MeV vaccine during 1980-2013 in this country, and the temporary absence of a 
functioning immunization program during and after the genocide in 1994. De-
spite these setbacks, immunity to MeV in Rwanda has substantially improved 
during recent years, as shown by the decreasing incidence of measles in the 
country. In light of these data, the threat of new larger outbreaks of measles 
within the country seems relatively low at present, despite the low seropreva-
lence. However, the situation in neighbouring countries should be observed with 
caution. 
 
 
 
 
  Rwanda Tanzania Burundi Uganda DRC 
Measles vaccine coverage 
 (mean (%)) 2003-2014 93,4 94 89 74 67 
Measles incidence, no. of 
cases (mean) 2003-2014 197 1827 184 4739 60910 
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4.2 Paper II  
 
ZIKV and RuV seroprevalences among Rwandan and Swedish blood donors 
were investigated. In particular, Rwandan women of childbearing age were as-
sessed for their susceptibility to these two viruses with the potency of causing 
fetal malformations through congenital infections. For RuV, the investigation of 
specific immunity was motivated by the recent introduction of general vaccina-
tion against this virus in Rwanda.  
4.2.1 Seroprevalence of ZIKV 
ZIKV IgG was detected in only 12 of the 874 Rwandan blood donors examined, 
resulting in a seroprevalence of 1.4 %. No Swedish donor was found to be posi-
tive for anti-ZIKV IgG antibodies.  
Of these 12 anti-ZIKV IgG antibody positive Rwandan samples, 5 were derived 
from the Eastern Province, 4 from the Southern Province, 2 from Kigali City, 
and 1 from the Western Province. All these anti-ZIKV IgG positive plasma sam-
ples tested negative for RT-PCR targeting this virus, arguing against ongoing 
infection in any of the subjects.  
From a total of 303 female Rwandan donors, 297 were of childbearing age (<45 
years). As only two of them had anti-ZIKV IgG antibodies, almost all the fe-
males of childbearing age were seronegative and thus susceptible to ZIKV 
(295/297, 99.3%).  
 
Recently, a low seroprevalence of ZIKV, 0.4%, was reported in healthy subjects 
from Ethiopia [195]. This low seroprevalence indicated an absence of herd im-
munity to this virus also in Ethiopia. Taken together, the two studies suggest that 
large populations of east Africans are susceptible to ZIKV, should new (or old) 
genotypes be introduced and start to circulate.  
Since infection of pregnant women with this virus might spread to the fetus to 
cause congenital malformations including microcephaly [196], the high rate of 
seronegativity in Rwandan women of childbearing age to ZIKV is a reason for 
concern. Although the global spread of ZIKV seems to have diminished at pre-
sent, preparedness for surveillance of this virus can be recommended.  
 
All the twelve Zika IgG positive samples were found to be negative on RT-PCR. 
Here, a missed diagnosis due to inappropriate timing of sampling, such as collec-
tions being done during the late phase of the infection, could not be completely 
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ruled out [143]. However, a more probable explanation for this negative finding 
could be the absence of active infection in Rwanda during the study period. 
But it should also be mentioned that flaviviruses are not regularly tested for 
among febrile patients in Rwanda at present, and that most such cases are diag-
nosed as “presumptive malaria” which is endemic in our country. In this context, 
a recent serological study conducted in hospitalized patients in Uganda, a neigh-
bouring country to Rwanda and the original site of isolation of ZIKV, indicated 
this virus as causing fever in singular cases[197]. However, confirmation by 
detection of viral RNA and/or genetic sequencing was not performed, thus fur-
ther studies are needed to settle the question whether ZIKV is currently circulat-
ing in the region.  
 
The low seroprevalence of ZIKV IgG observed in Rwanda is comparable to our 
findings in Swedish donors where no samples were seropositive to this virus. 
Despite the high abundance of mosquito vectors in Rwanda and its geographical 
location within a region endemic for flavivirus, our data argues against human 
spread of ZIKV in this country. However, the duration of immunity to this virus 
is largely unkown, and the half-life of anti-ZIKV IgG antibodies might be of 
short duration. If this is the case, i.e. that ZIKV does not confer a long-lasting 
protective immunity, a relatively recent circulation of this virus could not be 
ruled out.   
 
Rwanda has been classified by the Centers for Disease Control (CDC) as a coun-
try with high risk of ZIKV spread [198]. Results from our study showing a very 
low seroprevalence to ZIKV among blood donors in Rwanda might support this 
classification [199]. However, absence of an infection in a country might also be 
interpreted as a low risk for spread. As an example, the classification of Rwanda 
by the WHO as a high-risk country for yellow fever virus before 2014 [200] was 
followed by a changed estimation to that of a low-risk country [201]. This 
change was based on a survey on “Risk assessment of yellow fever virus circula-
tion in Rwanda” that was conducted in 2012 [202], and which showed low sero-
prevalence in humans and absence of the virus in mosquito vectors. Whatever 
the case, Rwandans travelling to ZIKV-endemic areas may presently be at high 
risk of infection, as almost all blood donors were found to be non-immune to this 
virus. Thus, pregnant women in Rwanda, as well as in Sweden, could be cau-
tioned against travelling to countries where ZIKV is endemic and congenital 
infections have been documented. 
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4.2.2 Seroprevalence of Rubella virus 
Seven samples from three females of childbearing age and four male Rwandan 
donors were not tested for anti-RuV IgG antibodies due to low sample volume.  
 
The seroprevalence to RuV IgG, investigated on 869 plasma samples from 
Rwandan blood donors, was high (91.9%), and comparable to that in their Swe-
dish counterparts (92.1%). Of the 300 Rwandan female donors, 89% tested posi-
tive to anti-RuV IgG antibodies. Of these, 294 were of childbearing age, from 
whom 31 (10.5%) were seronegative and thus susceptible to RuV. 
 
The high seroprevalence to RuV in Rwanda could only be explained by natural 
immunity, since the Rubella-containing vaccine (RCV) was recently (2013, 
catch-up for 15 years olds) introduced in Rwanda [189]. In contrast, the even 
higher seroprevalence of RuV IgG in the Swedish donors may result from a 
combination of natural immunity and of antibodies induced by the vaccine. Most 
likely, natural infection induces a stronger antibody response as compared to 
vaccination, which might explain the increase in seroprevalence as well as of 
increased anti-RuV IgG OD values with age in the Swedish cohort.  The finding 
that anti-RuV IgG OD values decreased with age in the Rwandan donors was 
probably caused by antibody decrement over time in this naturally infected 
population.  
 
As we can deduce from data presented in Table 8.4, RuV is circulating in Rwan-
da but not in Sweden at present. Fortunately, CRS cases have been absent in 
both countries during recent years, probably explained by high levels of immuni-
ty in their respective female populations. However, the negative reporting of 
CRS cases as presented in table 8.4, adapted from WHO data [188], might ques-
tion the quality of CRS diagnostics in Rwanda, but also in Sweden. Protective 
effects of vaccination against CRS cannot yet (2015) be anticipated in Rwanda. 
 
Table 8.4 Incidence of CRS, Rubella cases and RCV (%) in Rwanda and in 
Sweden over the last decade (2008 to 2017). Source: WHO. 
  Condition 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 
Rwanda CRS 0 0 0 - - 5 - - - - 
Sweden CRS 0 0 0 1 0 0 1 0 0 0 
            
Rwanda Rubella 22 15 1 15 50 172 62 36 34 35 
Sweden Rubella 0 0 0 0 0 50 4 3 1 0 
            
Rwanda RCV 99 95 99 97       
Sweden RCV 97 97 98 97 97 97 96 97 97 96 
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The continuous circulation of RuV in Rwanda (Table 8.4), despite such high 
seroprevalence justifies the introduction of general vaccination against this virus 
in Rwanda. Another support for RuV vaccination would be our finding of a rela-
tively high proportion of females among the non-immune donors in Rwanda. We 
found that 11% (33/300) of Rwandan females were seronegative to RuV as 
compared to only 6.5% (37/567) of the male donors, p<0.02. In addition, since 
the RuV antibody titers decreased with age among Rwandan subjects (Figure 2. 
B, paper II), women that become pregnant at advanced age [203] might be in-
fected and thus expose fetuses, with CRS as an end result. This is especially val-
id, as the improved hygiene and living condition of Rwandans may interrupt the 
booster from natural infection. Taken together, these factors justify the necessity 
of introducing and maintaining RuV vaccine within the Extended Program of 
Immunization in Rwanda. 
 
4.3 Paper III 
 
Seroprevalence of anti-CHIKV and anti-WNV IgG antibodies were investigated 
by analysis of plasma samples from 874 Rwandan and on serum samples from 
199 Swedish blood donors. Positive IgG results were related to the distribution 
of mosquito vectors, which were earlier identified in Rwanda. To assess for sero-
logical cross-reactivity between WNV and TBEV, IgG antibodies to the latter 
virus was also investigated. 
4.3.1 Seroprevalence of CHIKV 
Seroprevalence of IgG to CHIKV in Rwandan blood donors was found to be 
high (63%), but differently distributed among the provinces. The Eastern Prov-
ince in Rwanda reported the highest seroprevalence, 86.7%. In addition, Rwan-
dan donors > 26 years old showed a higher seroprevalence for CHIKV IgG 
(77%), as compared to the younger (≤ 25 years) subjects (51%). Swedish donors 
showed a low seroprevalence of 8.5%, with lower mean OD value to the CHIKV 
antigen (0.75 as compared to 1.5 of Rwandans) of the positive samples.  
 
The high seroprevalence of 63%, observed here among Rwandan blood donors, 
may predict an important circulation of CHIKV in Rwanda. Elsewhere in Africa, 
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a high seroprevalence to CHIKV was also reported. In 2004, the Busia District 
of Kenya reported a seroprevalence of 59.9% for CHIKV. In another study, con-
ducted between 2010 and 2012 in western Kenya, the CHIKV seroprevalence 
was even higher at 66.9% [204, 205]. To further support an actual circulation 
among humans in east Africa, CHIKV was also isolated in Kenyan patients, and 
mosquito vectors were investigated and found to be competent for CHIKV as 
well [206, 207]. In addition, CHIKV was the most common arbovirus identified 
in acute febrile Ugandan patients when samples collected during 2014-2017 
were analysed [197]. 
 
The lack of reported clinical cases in Rwanda might be explained by the shortage 
of diagnostic means, the lack of the awareness of arboviruses by medical doctors 
and the population in general, and above all the syndromic diagnostic approach 
by which Chikungunya fever might be misdiagnosed as malaria, an endemic 
parasitic mosquito-borne infection in Rwanda. On the other hand, the high sero-
prevalence of CHIKV in Rwanda might be a result of serological cross-reactivity 
within closely related alphaviruses [208], which was not investigated here. Espe-
cially the ONNV, which was found to be prevalent within African countries 
(Figure 8.4) where CHIKV is also prevalent (Figure 8.5), including those border-
ing Rwanda, should be investigated in future arboviral serostudies. 
 
 
Figure 8.4 African map with countries where ONNV was isolated in human, mosquitoes, or other 
animals [209]. With permission from Taylor & Francis. 
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Figure 8.5 Geographical distribution of endemic CHIKV and its primary vectors [210].  
 
 
As we were the first to use the p62-E1 antigen for anti-CHIKV IgG antibody 
investigation, we compared our results with a commercial test (Ab177835 anti-
Chikungunya IgG, Abcam) on 35 selected Rwandan samples, based on the 
strength of IgG OD values from the in-house antigen assay, and on 9 Swedish 
samples with different results. Only our strongly positive samples from Rwanda 
were comparable between both tests: 7 out of 9 were positive, one sample was 
found equivocal and another negative. The remaining Rwandan samples, the 
intermediate and weakly positive, and the seronegative samples, in addition to all 
9 Swedish samples, were found to be negative by the commercial test. We hy-
pothesized that our in-house test might be more sensitive, allowing the detection 
of IgG reactivity also in more weakly positive samples, which may explain the 
high seroprevalence. This antigen was designed as a vaccine candidate, and 
therefore should be specific enough to induce immunity to CHIKV. On the other 
hand, the commercial test, which was aimed for research only and not for diag-
nostics, might have been designed to be less sensitive in order to avoid detecting 
cross-reactive samples. However, it should be pointed out that the performance 
of our new ELISA assay remains to be tested in febrile patients with suspected 
arboviral infection, in order to correlate results with the outcome of PCR anal-
yses.  
 
The seroprevalence for CHIKV IgG of 8.5% among Swedish donors could be 
explained by travelling to southern Europe where outbreaks of CHIKV are re-
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ported [211-215], but also by possible cross-reactivity with Ockelbo virus, a 
Sindbis virus prevalent in Sweden [216-218]. 
 
The highest seroprevalence to CHIKV, which was found in the Eastern Province 
of Rwanda in our study, might be linked to reported circulation of CHIKV with-
in its bordering countries, Tanzania and Uganda. This finding coincides with the 
highest burden of malaria reported from the Eastern Province of Rwanda, to 
which four out of the top five districts with most of malaria cases belong to [14].  
 
The higher seroprevalence among older Rwandan donors compared to their 
younger counterparts and CHIKV IgG OD values that increase with age (Figure 
8.6) might predict a continuous exposure to CHIKV with enhancement of the 
immune response over time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 Distribution of CHIKV OD values with their trendline according to age of 
Rwandan blood donors.  
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4.3.2 Seroprevalence of WNV 
Rwandan donors showed a seroprevalence to WNV of 10.4%, and again the 
Eastern region was found to exhibit the highest seroprevalent (33.3%) of all 
provinces in Rwanda. Suprisingly, Swedish donors had a seroprevalence to 
WNV of 14.1%. 
 
Seroprevalences to WNV were reported earlier from several other African coun-
tries [219]. As an example, a low seroprevalence of 0.9% was reported from 
Ethiopia in the course of serostudies of yellow fever [195]. In Gabon, another 
study conducted in rural populations reported a higher seroprevalence of WNV 
IgG (27.2%), with local differences that could be related to the prevailing eco-
systems. The lakes region recorded the highest seroprevalence for WNV of all 
regions, 64.9% [220]. The high seroprevalence for WNV observed within the 
Eastern Province of Rwanda coincides with the collection of the highest number 
of Culex mosquitoes (>35%) reported there, but also with the highest seropreva-
lence to CHIKV suggesting an important activity of arboviruses in that area. Of 
73 samples showing dual positivity to WNV and CHIKV IgG among the Rwan-
dan blood donors, 42 (57.5%) samples were from the Eastern Province. As dis-
cussed above, this province shares boundaries with Tanzania and Uganda where 
infections caused by those two viruses are frequently diagnosed. 
 
The seroprevalence to WNV in Rwanda might also reflect serological cross-
reactivity to other flaviviruses prevalent within the east central African region 
such as dengue fever or yellow fever [221, 222]. 
The relatively high seroprevalence to WNV seen in Swedish donors might be 
explained by an exposure to WNV locally or as tourists, especially in southern 
Europe, but above all, by cross-reactivity with TBEV, a flavivirus endemic in 
Sweden. To this end, we investigated TBEV seroreactivity in Rwandan (n=91) 
and Swedish (n=28) donor samples that were positive to anti-WNV IgG antibod-
ies. Our results showed that 78.6% of Swedish donors were also positive for 
anti-TBEV IgG antibodies, with a higher mean OD value of 1.34, as compared 
to the mean OD value of 0.65 in samples from Rwandan donors who were sero-
positive to TBEV at a rate of 70.3%. Furthermore, the TBEV OD values of all 
the 91 Rwandan samples investigated were found to be lower than their corre-
sponding WNV OD values. In contrast, 13 of the 28 Swedish donors had higher 
OD values against the TBEV antigen as compared to their corresponding OD 
values for the WNV ELISA, suggesting that almost half of the Swedish subjects 
that were positive for anti-WNV IgG antibodies primarily were seropositive to 
TBEV and showed a serological cross-reactivity to WNV. This possible dual 
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serological cross-reactivity between TBEV and WNV was further investigated 
by pepscan analysis in Paper IV. 
 
4.4 Paper IV 
 
In paper III, we documented a probable serological cross-reactivity between the 
two flaviviruses WNV and TBEV. The aims of Paper IV were to further chal-
lenge and elucidate this cross-reactivity. After finding a similar seroprevalence 
to WNV in Rwandan (10.4%) and Swedish (14.1%) blood donors in Paper III, 
we tested the hypothesis that the Swedish WNV seropositive donors were IgG-
positive to TBEV rather than to WNV. This was the case, but somewhat surpris-
ingly the majority of Rwandan WNV seropositive donors were also seropositive 
to TBEV, possibly suggesting a bi-directional serological cross-reactivity. 
 
Here, we first performed a PRNT against TBEV on all 28 Swedish serum sam-
ples from donors positive to WNV. This test could only be performed on the 
Swedish samples, since the Rwandan samples consisted of plasma which had a 
probable toxic effect on the cultured cells used for the PRNT. In addition, we 
assayed for anti-WNV IgG antibodies in serum samples from 58 Swedish TBE-
patients who had previously tested IgM positive to TBEV. Finally, we mapped, 
by pepscan, amino acids sequences of linear epitopes through overlapping pep-
tides representing the glycoprotein E of WNV and of TBEV on four different 
pools of serum/plasma samples as defined in Materials and Methods, paper IV. 
Briefly, Swedish and Rwandan donors that were dually seropositive to WNV 
and TBEV were tested, with Swedish TBE patients included as controls. In addi-
tion, CSF samples that were IgG positive to TBEV were also pooled and includ-
ed for epitope mapping. Lastly, amino acids sequences of linear epitope were 
determined by analysis of reactivity of the pools to all the peptides. 
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4.4.1 Dual seroreactivity of Swedish samples to WNV and TBEV, and 
PRNT for TBEV 
Of 28 serum samples from Swedish donors that were anti-WNV IgG antibody 
positive, 22 (78.6%) were also positive for anti-TBEV IgG antibodies. Of these 
22 dually seroreactive samples, 18 (81.8%) tested positive for PRNT-TBEV, 
indicating a past TBEV infection or vaccination against this virus. Most likely, 
their anti-TBEV antibodies were cross-reactive with WNV. Further support for 
the existence of such a reactivity came from our testing of 58 TBEV IgM posi-
tive samples from notified TBE patients, when 31 (53.4%) of these samples also 
tested positive for WNV IgG. Since infections with these two viruses are rare 
events in the Swedish population, it is unlikely that any of the TBE patients also 
had experienced an infection with WNV.  
 
The high proportion of positive reactions in PRNT-TBEV from Swedish WNV 
seropositive donor samples could largely explain the surprisingly high seroprev-
alence to WNV found among Swedish blood donors. In 18/28 (64.3%) of these 
samples, anti-TBEV IgG antibodies were demonstrated. The one PRNT-TBEV 
positive sample, which was TBEV IgG negative, might be due to the high speci-
ficity of the PRNT compared to ELISA test. The high proportion of TBEV IgM 
positive samples from actual TBE patients that tested positive to WNV IgG un-
derscores this cross-reactivity. Although PRNT could not be performed on the 
Rwandan samples, the finding of much lower OD values of anti-TBEV IgG an-
tibodies from Rwandan samples seropositive to WNV suggests cross-reactivity 
from WNV to TBEV, i.e. the opposite direction of that found in the Swedish 
samples. Furthermore, this finding argued against circulation of TBEV in Rwan-
da. 
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4.4.2 Analysis of IgG reactivity to linear epitopes of the E protein of 
TBEV and WNV in Rwandan and Swedish samples  
Human serum pool 1, which consisted of confirmed TBE patients from Sweden, 
showed a moderate response against the TBEV peptide QKGSSIGRVFQKTKK 
and a very low response against WNV peptides WRNRETLMEF. This pool was 
drawn during an early phase of TBE, since these samples also were IgM positive 
to TBEV. Our findings suggest that the linear TBE epitope 
QKGSSIGRVFQKTKK evokes early IgG reactivity. 
 
Human serum pool 2, of Swedish donors who were WNV IgG positive but 
PRNT-TBEV negative, showed reactivity of diverse magnitudes against TBEV 
peptides, where again the sequence QKGSSIGRVFQKTKK had the highest flu-
orescent intensity, and against WNV peptides with DLTPVGRLVTVN as the 
main epitope. The results suggest dual immunity despite the negative TBEV 
serology in this pool, since the negative control showed less reactivity to both 
peptides. 
  
Human serum pool 3, of Swedish donors with WNV IgG positive and NT-TBEV 
positive, showed a moderate response against both the TBEV peptide 
QKGSSIGRVFQKTKK and the WNV peptide DSCVTIMSKDKPTID. Most 
likely, this pool demonstrated dual immunity. 
 
Human plasma pool 4, of Rwandan donors seropositive to both WNV and 
TBEV, showed the strongest and the most complex response in the pepscan 
analysis when compared to the Swedish pooled samples. Surprisingly, the 
Rwandan pooled sample showed a moderate to strong IgG response against 
TBEV peptides with the consensus motifs IVYTVKVEPHT, NETHSGRK, 
RKTASFTISSEKTI, AQNWNNAERLV, SGHVTCEVGLEK and 
SGHDTVVMEV, as compared to a weak to moderate IgG response against 
WNV peptides SCVTIMSKDKPTID, IKYEVAIFVHGPTTV, 
GTKTFLVHREWFMD, WRNRETLMEF, ALAGTIPVE and LFLSVNVHA. In 
addition to strengthening the serological finding of their WNV exposure, these 
results suggest that Rwandan donors could have been exposed to hitherto un-
known TBEV-like viruses. 
 
The human CSF pool 5 from confirmed TBE patients exhibited a weak but clear 
response against two TBEV peptides with the consensus motifs WQVHRDWFN 
and GAQNWNNAERLVE. Interestingly, the corresponding serum pool 1 
showed almost no reactivity to these peptides, arguing for a selective (or earlier) 
exposure of these linear epitopes within the CNS. There were no visible respons-
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es from the CSF pool against any peptides of the WNV variant of glycoprotein 
E. 
 
In summary, the three Swedish serum pools showed some similarities in reaction 
to linear peptides of both WNV and TBEV (Figure 8.7). Their fluorescence in-
tensity was higher for peptides representing TBEV as compared to WNV, except 
for the pool 2, seronegative to TBEV, where the fluorescence intensity was 
slightly higher for WNV. There were no obvious sequence similarities among 
the epitopes defined above, from glycoprotein E of WNV and TBEV, that could 
explain the serological cross-reactivity that we found by ELISA tests against 
these two viruses in paper III. Although detailed documentation of the antigens 
of these two commercial tests is lacking, they most likely contain, in addition to 
their respective E proteins, several other viral and cellular proteins that could 
influence cross-reactivity.  
 
The CSF pool from the Swedish TBE patients showed weak to moderate re-
sponse against two TBEV epitopes only. These peptides represent the first linear 
and intrathecal TBEV-epitopes described, and they might well be specific and 
could therefore serve to distinguish anti-TBEV IgG from antibodies reactive 
with other flaviviruses, in the future. The other main finding was that Rwandan 
plasma samples reacted with several TBE-peptides of which some were con-
served across the hitherto sequenced members of the sub-family of tick-borne 
flaviviruses. Such viruses should be sought for in Rwandan patients with CNS 
infections. 
 
	
Figure 8.7 Comparison of the antibody responses of human serum pools 1, 2, 3 and 4 and CSF pool 
5. The strongest response was found for serum pool 4 against epitopes of TBEV and 
WNV glycoprotein E variants, while CSF pool 5 only responded against epitopes of 
TBEV. 
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5. Conclusions 
We have, for the first time in Rwanda, conducted seroepidemiological studies of 
two vaccine-preventable viruses, MeV and RuV. The seroprevalence of MeV 
among Rwandan blood donors was low, probably as a result of only one dose of 
MeV vaccine being provided until 2013. This susceptibility to MeV in large 
parts of the population may lead to future outbreaks of measles, especially 
among Rwandan subjects of young age (<35 years old) who had the lowest sero-
prevalence (64.8%). Most likely, this risk situation will be improved by the re-
cent introduction of the second dose of MeV vaccine. In addition, the high MeV 
vaccine coverage rate (>90%) and the limited and decreasing number of measles 
cases reported in Rwanda are indicators of a well functioning immunization pro-
gram. Furthermore, the MeV strains detected in Rwanda during the 2010-2011 
outbreak may have been imported, as the B3 genotype found by sequencing were 
suggested to originate from the DRC. 
 
In general, the seroprevalence for RuV among Rwandan donors was high and 
reached levels comparable to that of Swedish blood donors. However, unlike the 
findings in samples from Swedish donors, antibodies to RuV were decreasing 
with age among Rwandan donors, who only had been naturally infected. A rela-
tively high number of Rwandan female donors of childbearing age were found to 
be seronegative to RuV (10.5%), which indicated an increased risk of developing 
congenital infection with possible CRS. In addition to the recently introduced 
general immunization against RuV, a vaccination campaign specifically target-
ing this group seems warranted. 
 
In the same population of donors, we also assessed the immunity to three mos-
quito-borne viruses in Rwanda: ZIKV, CHIKV and WNV. Most Rwandan blood 
donors were seronegative to ZIKV, and therefore susceptible to infection with 
this virus. Especially females of childbearing age are at risk should the virus start 
to circulate in Rwanda. The ZIKV IgG positive samples were negative on ZIKV 
RT-PCR, thus arguing against a current circulation of ZIKV in Rwanda. Howev-
er, the identification of mosquito vectors of ZIKV in Rwanda is an observadum, 
and a preparedness plan of preventive measures can be recommended.  
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In contrast, Rwandan blood donors showed a high seroprevalence to CHIKV, 
which increased with age, suggesting an extensive and continuous circulation of 
this virus in Rwanda. We recommend that infection with CHIKV should be con-
sidered among several differential diagnoses in febrile patients. In this context, 
our new serological test could be useful. Though a low seroprevalence to WNV 
was reported from Rwandan donors, the highest seroprevalence (>33%) found 
within the Eastern Province indicated the importance of considering also WNV 
while managing febrile patients from this region. Furthermore, its vector, Culex, 
was the most abundant mosquito species identified in that area. In addition, the 
dual seropositivity to CHIKV and WNV seen among Rwandan donors from the 
eastern region, and the relative abundance of Aedes and Culex mosquitoes sug-
gested an important co-circulation of these two arboviruses in Rwanda. Swedish 
donors presented a low seroprevalence of CHIKV IgG, probably due to a limited 
exposure. 
 
Lastly, we found a possible serological cross-reactivity between the two fla-
viviruses WNV and TBEV. This was suspected due to a relatively high sero-
prevalence of WNV IgG in Sweden (14.1%) as compared to Rwanda (10.4%). 
Surprisingly, a large majority of the WNV seropositive donors from both coun-
tries were reactive also in the TBEV test. Furthermore, in Rwandan blood donors 
we found a reactivity to several TBEV-related linear epitopes, which seemed 
completely conserved within the tick-borne flaviviruses, suggesting a circulation 
of unknown tick-borne flaviviruses in Rwanda. To conclude, future diagnostic 
study of febrile patients should include sequencing studies that may contribute to 
the discovery of such viruses, and improve our understanding of the febrile pa-
tient’ syndrome. 
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6. Future Perspectives 
The seroprevalence studies of MeV and RuV in this thesis could serve as a base-
line for future evaluations of the general vaccination program in Rwanda. The 
low seroprevalence of MeV, with immunity provided by natural infection or by 
one dose of MeV vaccine, raises a question regarding MeV vaccine efficacy in 
relation to the MeV strains circulating in Rwanda. Thus, the effect of the second 
dose of MeV vaccine, introduced in 2014, should be serologically investigated 
and compared to our baseline results. We anticipate that the switch from one 
dose to two doses of the vaccine will greatly improve the here documented low 
seroprevalence for MeV in Rwanda over time. But such an expected improve-
ment could be counteracted by a low circulation of MeV in the future, since the 
effect of natural boosting will diminish. The external pressure from neighbour-
ing states as regards MeV will most likely continue for some time, why serosur-
veillance of immunity to this virus should be continued in Rwanda.  
 
In the same context, the high seroprevalence for RuV, that however decreases 
with age, is presently related to natural infection only. Our finding of seronega-
tivity in a relatively large proportion of women of childbearing age should be 
followed up by vaccination, for example at maternal and child health (MCH) 
clinics. Although catch-up vaccination of teenagers against RuV has been carried 
out in Rwanda, in addition to the recently introduced national RuV immuniza-
tion program of children, serotesting during pregnancy and vaccination of IgG-
negative subjects could be recommended.  
 
 
The seroepidemiology for ZIKV in Rwanda was, in essence, negative. This is a 
strong indication against a spread of ZIKV in Rwanda, which should be benefi-
cial from a general health aspect. On the other hand, this finding indicates a risk 
of future spread of the virus, since the population is non-immune. We recom-
mend a continued awareness of the dynamic spread of ZIKV globally, not least 
as regards introduction of Pacific-American strains into Africa. To this end, im-
proved diagnostics could be developed, including ZIKV and RuV among the 
microbial agents sought for, when investigating suspected congenital infections 
and/or malformations in Rwanda.   
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As a consequence of the here described high seroprevalence of CHIKV in 
Rwanda, febrile patients should be screened for CHIKV RNA, but also for other 
medically important arboviruses such as Dengue, O’nyong-nyong, and Rift Val-
ley fever viruses which are frequently reported from this region of Africa. The 
introduction of such PCR tests will improve the management of patients who 
presently are classified as having “presumed malaria”. Likewise, the screening 
of WNV RNA from febrile patients with/without meningo-encephalitis may be 
also justified, at least in the Eastern Province with regards to the reported sero-
prevalence and the abundance of Culex mosquitoes in this part of Rwanda.  
 
The probable serological cross-reactivity between viruses of the same families 
such as between ONNV with CHIKV, or Dengue virus with WNV, but also of 
other genetically related arboviruses that share the same vector should be inves-
tigated. This is certainly valid because of the high seroprevalence shown for 
CHIKV and WNV, and the highest abundance of Culex and Aedes mosquitoes 
found in the Eastern Province of Rwanda. Finally, the reactivity to a TBE-related 
linear epitope found in Rwandan blood donors raise the suspicion of the pres-
ence of unknown tick-borne flavivirus(es) in Rwanda, which should be investi-
gated for. To this end, there is a need also for investigating the prevalence of 
different species of ticks in Rwanda, in addition to Culex and Aedes mosquitoes, 
and their respective vector competency for transmission of arboviruses.  
 
In summary, this thesis has contributed to the diagnostic development and im-
plementation within the field of clinical virology in Rwanda. We anticipate that 
such development will contribute to the combat of medically important viruses, 
which may improve the general health of the population, not least for children 
and their mothers. 
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